  
1 
CONFIDENTIAL  
 
 
TRADIPI[INVESTIGATOR_894569]. 9 TO VP-VLY -686-2301  
 
 
A MULTICENTER, RANDOMIZED,  DOUBLE -BLIND , 
PLACEBO -CONTROLLED  STUDY TO ASSESS THE 
EFFICACY OF TRADIPI[INVESTIGATOR_909264] : Gunther Birznieks   
Document Type:       Clinical Study Protocol  
Sponsor:         Vanda Pharmaceuticals Inc.  
          [ADDRESS_1276516]:       tradipi[INVESTIGATOR_053] ( VLY-686) 
Protocol Number:      VP-VLY-686-2301  
Study Phase:        IIa 
IND Number:        131545  
 
 
Date :  26 November 2018  
Status: Final  
Number of Pages:  95 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
2 
CONFIDENTIAL  SIGNATURE [CONTACT_522477].  
 
VP-VLY -686-2301 Amendment No. 9 
 
Approved by [CONTACT_716]:  
 
Program Lead :    
 Gunther Birznieks    Date  
 Senior  Vice President, Research 
& Development Committee  
    
    
Medical Director :    
 Christos Polymeropoulos , M.D.  Date  
 Medical Director    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
3 
CONFIDENTIAL  Name [CONTACT_790]/Company:  
Vanda Pharmaceuticals Inc.  
Name [CONTACT_791]:  
Tradipi[INVESTIGATOR_053] (VLY -686) 
Name [CONTACT_3261]:  
{2-[1-(3,5-Bistrifluoromethylbenzyl) -5-pyridin -4-yl-1H-[1,2,3]triazol -4-yl]-pyridin -3-yl}-(2-
chlorophenyl) -methanone  
Title of Study: A Multicenter, Randomized, Double -Blind, Placebo -Controlled Proof of Concept Study 
to Assess the Efficacy of Tradipi[INVESTIGATOR_909265](s): approximately 30  centers in the [LOCATION_002]  
Indication:  
Diabetic & Idiopathic Gastroparesis  Phase of development:  
IIa 
Number of subjects (planned):  
Approximately 150 subjects randomized to 2 arms ( 75 per arm, 1:1 randomization scheme)  
Inclusion Criteria:  
1. Male and female subjects aged 18 – 70 years (inclusive);  
2. Diagnosed with idiopathic or diabetic gastroparesis with moderate to severe nausea:  
a. Demonstrated delayed gastric emptying of a solid meal via either scintigraphy or gastric 
breath test within [ADDRESS_1276517] 24 screening diary entries,  
NOTE:  CRITERIA 2 D-E ARE CONFIDENTIAL AND SHOULD NOT BE SHARED 
WITH SUBJECTS, POTENTIAL SUBJECTS, OR ANYONE OUTSIDE OF THE 
IMMEDIATE STUDY TEAM.  
d. mGCSI individual nausea score ≥ 3 at Visit 1,  and 
e. Average daily diary nausea severity ≥ [ADDRESS_1276518] 50% days of nausea during 
the screening period;  
3. Patient ’s gastroparesis symptoms persist despi[INVESTIGATOR_522463]/or life -style modifications;  
4. Body Mass Index (BMI) of ≥18 and ≤38 kg/m2 (BMI = weight (kg)/ [height (m)]2);  
5. Subjects must agree to the following study restrictions:   
a. Males of procreative capacity (not surgically sterile) will use an acceptable method of 
contraception from randomization through [ADDRESS_1276519] -menopausal  partner;  
b. Females of child -bearing potential (not surgically sterile or post -menopausal, defined as 12 
months without menses) will use an acceptable method of contraception from 1 month prior 
to randomization (or screening, if earlier) through [ADDRESS_1276520] dose of study 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
4 
CONFIDENTIAL  medication. Examples of acceptable methods of contraception for females include 
abstinence, double barrier method, IUD, hormonal contraception, or sterilized partner;  
6. Ability and acceptance to provide written informed consent;  
7. Willing to participate i n the pharmacogenomics sample collection ; 
8. Willing and able to comply with all study requirements and restrictions, including but not limited 
to:  
a. daily symptom diary completion , 
b. prohibited medications , and  
c. strict control of blood g lucose (T1DM and T2DM patients);  
9. Willing to not participate in any other interventional trial for the duration of their participation.  
Exclusion Criteria:  
1. Another active disorder or treatment which could explain or contribute to symptoms in the 
opi[INVESTIGATOR_689] (including but not limited to gastric malignancy, neurological 
disorder, or heavy doses of strong anticholinergics);  
2. Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, post -surgical cause of 
gastroparesis, or gastric stimulation device surgically implanted within the last year or if 
implanted more than a year ago, have changed stimulation settings wi thin the last 3 months (ie 
gastric stimulation device must have a stable setting for at least 3 months);  
3. Gastric or par enteral feeding  within 4 weeks of screening ;  
4. Pregnancy or nursing;  
5. History of intolerance and/or hypersensitivity to medications similar to tradipi[INVESTIGATOR_522465];  
6. History (including family history) or current evidence of congenital long QT syndrome or 
known acquired QT interval prolongation  (including QTc >  450 in males or >  470 in females  at 
screening ); 
7. History of suicide attempt and/or suicidal ideation (of type 4 or 5 on the Columbia Suicide 
Severity Rating Scale (C -SSRS)) within [ADDRESS_1276521] is at risk of suicide at 
Screening or Baseline, in the opi[INVESTIGATOR_871];  
8. History of an eating disorder within 2 years of screening;  
9. Recent history (within six months of screening) of Alcohol Use Disorder or Substance Use 
Disorder as defined in DSM -5 or evidence of such abuse which may include a positive drug 
screen at the Screening visit;  
10. Uncontrolled thyroid disease ;  
11. Unstable cardiac, respi[INVESTIGATOR_696], hepatic or renal disease;  
12. Evidence of uncontrolled blood glucose (including HbA1C >[ADDRESS_1276522] 60 
days);  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
5 
CONFIDENTIAL  13. Indication of impaired liver function (including values for AST, ALT, or bilirubin > 1.5 times 
the Upper Limit of Normal, unless isolated bilirubin > 1.[ADDRESS_1276523] due solely to Gilbert’s 
syndrome);  
14. Has a creatinine level > 1.[ADDRESS_1276524];  
15. Use of prohibited medication or medication wit h anti -nausea, antiemetic, neuro modulating, or 
prokinetic effect within 2 weeks of th e screening visit EXCEPT when administered on a stable 
daily dosing schedule (stable for at least 3 months prior to the screening visit) or administered 
under protocol -specified rescue medication guidelines;  
16. Use of the following within 2 weeks of screening: another  NK-[ADDRESS_1276525], phenergan more than 2 times per day, or opi[INVESTIGATOR_909266] 2 times per week ;  
17. Pyloric injection of neurotoxins (e.g.  botulinum type A or B) within 3  months of the Screening 
Visit;  
18. Exposure to any investigational medication, including placebo or domperidone, within 60 days 
of the Baseline Visit;   
19. Anyone affiliated with the site or sponsor and/or anyone who may consent under duress; and  
20. Any other reason as determined by [CONTACT_894577] -
benefit of study participation, may interfere with study compliance, or may confound study 
results.  
Investigational product, dosage and mode of administration:  
Oral 85 mg tradipi[INVESTIGATOR_909267] s will be administered . Subjects will be randomized 
to one of t wo treatment arms to receive 85 mg tradipi[INVESTIGATOR_909268].  All subjects will be instructed 
to take 1 capsule in the morning and another approximatel y 12 hours later in the evening.  
Duration of treatment:  Double Blind Evaluation Phase: 4 weeks  
 
Open Label Extension (OLE) Phase : 8 weeks  
Continued Open Label Extension  (COLE)  Phase: additional 52 weeks  
Objectives:  
Primary:  
• To evaluate the efficacy of tra dipi[INVESTIGATOR_909269].  
Secondary:  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909270]  
• To evaluate the efficacy of tradipi[INVESTIGATOR_522472]  
• To evaluate the efficacy of tradipi[INVESTIGATOR_522473]  
• To explore the safety and tolerability of multiple oral doses of tradipi[INVESTIGATOR_053].  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
6 
CONFIDENTIAL  Overall Design:  
This is a multi center, randomized, double -blind, placebo -controlled study to be conducted in the United 
States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria 
for the study, will be randomized to one of t wo treatment groups. Randomization will be stratified by 
[CONTACT_522476] (idiopathic or diabetic), and enrollment for either of the etiologies will be capped at 60% 
of the total sample size.  
The study is divided into four phases: the screening phase , the evaluation phase , the open label extension 
phase , and the continued open label extension phase . The screening phase includes a screening visit to 
evaluate subjects’ preliminary eligibility for the study. During the screening phase, subjects will collect 
diary data for at least 4 weeks. The evaluation phase includes 4 weeks of randomized double -blind 
treatment. Daily diaries will be completed during all phases. Clinical evaluations will occur at  Screening, 
Baseline, Week 2 and Week 4. At the end of the 28-day evaluation  phase, those subjects who completed 
this phase will enroll into an 8-week open -label extension (OLE) , where each subject will either continue 
(if previously on active) or be switched to (if previously on placebo) the same daily dose of tradipi[INVESTIGATOR_909271] (85 mg bid, approximately 12 hours apart).  Patients who complete 
the 8 week open -label extension phase will return for a 52 week continued open label extention phase  
(COLE) .  
Primary Endpoint:  
Change from baseline to Day 28 in weekly average of daily i ndividual nausea severity scores (0=none, 
1=very mild, 2= mild, 3=moderate, 4=severe, 5=very severe)  
 
Criteria for evaluation:  
Efficacy :  
Efficacy assessments will include:  
• Gastroparesis Core Symptom Daily Diary (GCSDD)  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified Patient Assessment of Upper GI Disorders – Symptoms (mPAGI -SYM)  
• Patient Global Impression – Change (PGI -C) 
• Patient Assessment of Upper Gastrointestinal Disorders – QOL (PAGI -QOL)  
• Gastr oparesis Treatment Benefit Survey  (GTBS)  
• Clinician Global Impression – Severity (CGI -S) 
Safety:  
• Safety and tolerability assessments will include the recording of adverse events (AEs), 
physical examinations, clinical laboratory evaluations, vital signs, and electrocardiograms.  
• The Columbia -Suicide Severity Scale (C -SSRS) will be used to assess suicidal behavior and 
ideation.  
Sample Size Discussion:  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276526] with the 5% significance level, the planned sample size of 75 subjects per arm 
provides 8 6% power to detect a mean difference of 0.[ADDRESS_1276527] deviation of 1.6 in each treatment group.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276528] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ............................. 16 
3. INTRODUCTION  ................................ ................................ ................................ ......20 
3.1. Background  ................................ ................................ ................................ ................. 20 
3.2. Tradipi[INVESTIGATOR_909272]  ................................ ................................ .......... 21 
3.2.1.  Nonclinical Pharmacology and Toxicology  ................................ ............................... 21 
3.2.2.  Clinical  ................................ ................................ ................................ ........................ 21 
4. TRIAL OBJECTIVES AND RATIONALE  ................................ .............................. 24 
4.1. Objectives  ................................ ................................ ................................ ................... 24 
4.1.1.  Primary  ................................ ................................ ................................ ....................... 24 
4.1.2.  Secondary  ................................ ................................ ................................ ................... 24 
4.1.3.  Exploratory  ................................ ................................ ................................ ................. 24 
4.2. Rationale  ................................ ................................ ................................ ..................... 24 
4.2.1.  Study Rationale  ................................ ................................ ................................ ........... 24 
4.2.2.  Rationale for Dose and Study Design  ................................ ................................ ......... 25 
4.2.3.  Risk and Benefit  ................................ ................................ ................................ ......... 25 
5. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 26 
5.1. Overall Study Design and Plan: Description  ................................ .............................. 26 
5.1.1.  Screening Phase  ................................ ................................ ................................ .......... 26 
[IP_ADDRESS].  Screening Visit (Visit 1)  ................................ ................................ ............................. 26 
[IP_ADDRESS].  Baseline Visit (Visit 2)  ................................ ................................ ............................... 27 
5.1.2.  Evaluation Phase  ................................ ................................ ................................ ......... 28 
[IP_ADDRESS].  Visit 3  ................................ ................................ ................................ .......................... 28 
[IP_ADDRESS].  End of Phase or Early Termination (Visit 4)  ................................ .............................. [ADDRESS_1276529] Withdrawal Criteria  ................................ ................................ ....................... 34 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
9 
CONFIDENTIAL  7. TREATMENT OF SUBJECTS – EVALUATION PHASE  ................................ ......36 
7.1. Study Medication  ................................ ................................ ................................ ........ 36 
7.1.1.  Dosing  ................................ ................................ ................................ ......................... 36 
7.1.2.  Guidance for Taking Study Medication  ................................ ................................ .....36 
7.2. Concomitant Medications  ................................ ................................ ........................... 36 
7.2.1.  Prohibited Medications  ................................ ................................ ............................... 36 
7.2.2.  Rescue Medication  ................................ ................................ ................................ ......37 
[IP_ADDRESS].  Rescue Medication Guidelines  ................................ ................................ ................... [ADDRESS_1276530] Replacement  ................................ ................................ ................................ ..39 
7.4.3.  Randomization  ................................ ................................ ................................ ............ 39 
8. STUDY MEDICATION MATERIALS AND MANAGEMENT  ............................. 40 
8.1. Study Medication  ................................ ................................ ................................ ........ 40 
8.2. Study Medication Packaging and Labeling  ................................ ................................ 40 
8.3. Study Medication Storage  ................................ ................................ ........................... 40 
8.4. Study Medication Accountability  ................................ ................................ ............... 40 
9. STUDY ASSESSMENTS – EVALUATION PHASE  ................................ ............... 42 
9.1. Study Assessments per Visit  ................................ ................................ ....................... 42 
9.1.1.  Screening Visit (Visit 1)  ................................ ................................ ............................. 42 
9.1.2.  Baseline Visit (Visit 2, Study Day 0)  ................................ ................................ ......... 42 
9.1.3.  Visit 3 (Study Day 14 ± 3 days)  ................................ ................................ ................. 43 
9.1.4.  Visit 4 (Study Day 28 ± 3 days)  ................................ ................................ ................. 44 
9.1.5.  Unscheduled Visits  ................................ ................................ ................................ .....45 
10. ASSESSMENT OF EFFICACY  ................................ ................................ ................ 46 
10.1.  Patient Reported Outcome (PRO) Assessments  ................................ ......................... 46 
10.1.1.  Gastroparesis Core Symptom Daily Diary (GCSDD)  ................................ ................ 46 
10.1.2.  Modified Gastroparesis Cardinal Symptom Index (mGCSI)  ................................ .....46 
10.1.3.  Modified Patient Assessment of Gastrointestinal Disorders – Symptoms 
(mPAGI -SYM)  ................................ ................................ ................................ ........... 46 
10.1.4.  Patient Global Impression -Change (PGI -C) ................................ ............................... 47 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
10 
CONFIDENTIAL  10.1.5.  Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life 
(PAGI -QOL)  ................................ ................................ ................................ ............... 47 
10.1.6.  Gastroparesis Treatment Benefit Survey (GTBS)  ................................ ...................... 47 
10.2.  Clinician Global Impression of Severity (CGI -S) ................................ ...................... 47 
10.3.  Pharmacokinetic Assessment  ................................ ................................ ...................... 47 
11. ASSESSMENT OF SAFETY  ................................ ................................ ..................... 48 
11.1.  Safety Parameters  ................................ ................................ ................................ .......48 
11.1.1.  Safety ECG  ................................ ................................ ................................ ................. 48 
11.1.2.  Laboratory Evaluations  ................................ ................................ ............................... 48 
[IP_ADDRESS].  Additional Laboratory Evaluations  ................................ ................................ ............. 49 
11.1.3.  Vital Signs and Body Measurements  ................................ ................................ .......... 49 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 49 
[IP_ADDRESS].  Body Measurements  ................................ ................................ ................................ ...50 
11.1.4.  Medical History and Physical Examinations  ................................ .............................. 50 
11.1.5.  Pregnancy  ................................ ................................ ................................ ................... 50 
11.1.6.  Columbia -Suicide Severity Rating Scale (C -SSRS)  ................................ ................... 51 
11.1.7.  Definitions Related to Safety  ................................ ................................ ...................... 51 
[IP_ADDRESS].  Adverse Event  ................................ ................................ ................................ ............. 51 
[IP_ADDRESS].  Serious Adverse Event  ................................ ................................ ................................ 51 
[IP_ADDRESS].  Adverse Event Follow -Up ................................ ................................ .......................... 52 
[IP_ADDRESS].  Adverse Event Reporting Period  ................................ ................................ ................ 52 
[IP_ADDRESS].  Pre-Existing Condition  ................................ ................................ ............................... 53 
11.1.8.  Relationship to Study Medication  ................................ ................................ .............. 53 
11.1.9.  Recording Adverse Events  ................................ ................................ ......................... 53 
[IP_ADDRESS].  Adverse Events During Study Period  ................................ ................................ ......... 53 
[IP_ADDRESS].  Post-Study Adverse Event  ................................ ................................ .......................... 54 
[IP_ADDRESS].  Abnormal Laboratory Values  ................................ ................................ ..................... 54 
11.1.10.  Reporting Adverse Events  ................................ ................................ .......................... 54 
[IP_ADDRESS].  Study Sponsor Notification by [CONTACT_10670]  ................................ ............................... 54 
[IP_ADDRESS].  Reporting of Events to Regulatory Authorities and IRB/EC  ................................ ......55 
11.1.11.  Unblinding Procedures  ................................ ................................ ............................... 55 
12. PHARMACOGENOMICS ASSESSMENT  ................................ .............................. 56 
13. STATISTICS  ................................ ................................ ................................ .............. 57 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276531] Disposition  ................................ ................................ ................................ .....58 
13.2.4.  Demography and Other Baseline Data  ................................ ................................ .......58 
13.2.5.  Study Medication  ................................ ................................ ................................ ........ 59 
13.2.6.  Prior/Concomitant Therapy  ................................ ................................ ........................ 59 
13.3.  Efficacy Data Analysis  ................................ ................................ ............................... 59 
13.3.1.  Primary Outcome  and Methodology  ................................ ................................ ......... 59 
13.3.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 60 
13.4.  Safety Data Analysis  ................................ ................................ ................................ ...60 
13.4.1.  Adverse Events  ................................ ................................ ................................ ........... 61 
13.4.2.  Laboratory Data  ................................ ................................ ................................ .......... 61 
13.4.3.  Vital Signs and Body Measurements  ................................ ................................ .......... 62 
13.4.4.  Electrocardiogram (ECG)  ................................ ................................ ........................... [ADDRESS_1276532] KEEPI[INVESTIGATOR_1645]  ................................ ...................... 67 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
12 
CONFIDENTIAL  17.1.  Retention of Records  ................................ ................................ ................................ ..67 
18. ADMINISTRATIVE PROCEDURES  ................................ ................................ .......68 
18.1.  Changes to the Protocol  ................................ ................................ .............................. 68 
18.2.  Discontinuation of Study  ................................ ................................ ............................ 68 
18.3.  Publication of Results  ................................ ................................ ................................ .69 
18.4.  Investigator Agreement  ................................ ................................ .............................. 70 
19. REFERENCES  ................................ ................................ ................................ ........... 71 
20. APPENDICES  ................................ ................................ ................................ ............ 73 
20.1.  Open -Label Extension Phase  ................................ ................................ ...................... 73 
20.1.1.  Phase Objective  ................................ ................................ ................................ .......... 73 
20.1.2.  Phase Rationale  ................................ ................................ ................................ ........... 73 
20.1.3.  Study Design for OLE Phase  ................................ ................................ ...................... 73 
20.1.4.  Selection and Withdrawal Criteria of Subjects for the OLE Phase  ............................ 76 
[IP_ADDRESS].  Inclusion Criteria  ................................ ................................ ................................ ........ 76 
[IP_ADDRESS].  Early Withdrawal of Subjects  ................................ ................................ ..................... 76 
20.1.5.  Study Medication  ................................ ................................ ................................ ........ 77 
[IP_ADDRESS].  Dosing  ................................ ................................ ................................ ......................... 77 
[IP_ADDRESS].  Guidance for Taking Study Medication  ................................ ................................ .....77 
20.1.6.  Concomitant Medication During the OLE Phase  ................................ ....................... 77 
[IP_ADDRESS].  Prohibited Medication  ................................ ................................ ................................ 77 
[IP_ADDRESS].  Rescue Medication  ................................ ................................ ................................ ......77 
20.1.7.  Treatment Compliance  ................................ ................................ ................................ 78 
20.1.8.  Treatment Assignment  ................................ ................................ ................................ 78 
20.1.9.  Study Drug, Packaging, and Labeling  ................................ ................................ ........ 78 
20.1.10.  Assessments Performed During the OLE  ................................ ................................ ...78 
[IP_ADDRESS].  Visit 4a (Only for subjects that completed the Double -Blind Phase prior to 
the OLE being available)  ................................ ................................ ............................ 78 
[IP_ADDRESS].  Visit 5 (Study Day 56 +/ - 3 days)  ................................ ................................ ............... 79 
[IP_ADDRESS].  Visit 6 (Day 84/EOS ± 3 days or ET)  ................................ ................................ ......... 80 
20.1.11.  Efficacy Assessments  ................................ ................................ ................................ .80 
20.1.12.  Safety Assessments  ................................ ................................ ................................ .....80 
20.1.13.  Statistical Methods  ................................ ................................ ................................ ......81 
20.2.  Continued Open Label Extension Phase  ................................ ................................ .....82 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
13 
CONFIDENTIAL  20.2.1.  Phase Objectives  ................................ ................................ ................................ ......... 82 
[IP_ADDRESS].  Primary  ................................ ................................ ................................ ....................... 82 
[IP_ADDRESS].  Secondary  ................................ ................................ ................................ ................... 82 
20.2.2.  Phase Rationale  ................................ ................................ ................................ ........... 82 
[IP_ADDRESS].  Study Rationale  ................................ ................................ ................................ ........... 82 
[IP_ADDRESS].  Rationale for Dose and Study Design  ................................ ................................ ......... 82 
[IP_ADDRESS].  Risk Benefit  ................................ ................................ ................................ ................ 83 
20.2.3.  Investigational Plan  ................................ ................................ ................................ ....83 
[IP_ADDRESS].  Overall Phase Design and Plan: Description  ................................ .............................. 83 
[IP_ADDRESS].  Screening Visit COLE -Visit 1 -A (Day 0)  ................................ ................................ ..84 
[IP_ADDRESS].  Screening Visit COLE -Visit 1 -B (Day 0)  ................................ ................................ ...84 
[IP_ADDRESS].  COLE Visit 2 -Visit 6 (Day 28, Day 84, Day 140, Day 196, Day 280  ± 5 
days)  ................................ ................................ ................................ ............................ 85 
[IP_ADDRESS].  Monthly Call to Subjects to Assess Health (Day 56, Day 112, Day 224, Day 
252, Day 308, Day 336,  ± 3 days)  ................................ ................................ ............. 85 
[IP_ADDRESS].  End of Study or Early Termination COLE Visit 7 (Day 364 ± 7 days)  ..................... 85 
20.2.4.  Selection and Withdrawal Criteria of Subjects for the OLE Phase  ............................ 87 
[IP_ADDRESS].  Inclusion Criteria  ................................ ................................ ................................ ........ 87 
[IP_ADDRESS].  Early Withdrawal of Subjects  ................................ ................................ ..................... 87 
20.2.5.  Treatment of Subjects  ................................ ................................ ................................ .88 
[IP_ADDRESS].  Dosing  ................................ ................................ ................................ ......................... 88 
[IP_ADDRESS].  Guidance for Taking Study Medication  ................................ ................................ .....88 
20.2.6.  Concomitant Medication During the COLE Phase  ................................ .................... 89 
[IP_ADDRESS].  Prohibited Medication  ................................ ................................ ................................ 89 
[IP_ADDRESS].  Rescue Medication  ................................ ................................ ................................ ......89 
20.2.7.  Treatment Compliance  ................................ ................................ ................................ 89 
20.2.8.  Treatment Assignment  ................................ ................................ ................................ 90 
20.2.9.  Study Drug, Packaging, and Labeling  ................................ ................................ ........ 90 
20.2.10.  Study Medication Materials and Management  ................................ ........................... 90 
20.2.11.  Study Assessments per Visit  ................................ ................................ ....................... 90 
[IP_ADDRESS].  COLE Screening Visit A or B (Visit 1, COLE Day 0)  ................................ ............... 90 
[IP_ADDRESS].  COLE Visit 2 -Visit 6 (COLE Day 28, Day 84, Day 140, Day 196, Day 280, 
± 5 days)  ................................ ................................ ................................ ..................... 91 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
14 
CONFIDENTIAL  [IP_ADDRESS].  COLE Visit 7/End of Study/Early Termination (COLE Day 365, ± 7 days)  ............. 92 
[IP_ADDRESS].  Unscheduled Visits  ................................ ................................ ................................ .....92 
[IP_ADDRESS].  Monthly Calls to Patients (COLE Day 56, Day 112, Day 224, Day 252, Day 
308, Day 336, ± 3 days)  ................................ ................................ .............................. 93 
20.2.12.  Efficacy Assessments  ................................ ................................ ................................ .93 
20.2.13.  Safety Assessments  ................................ ................................ ................................ .....93 
20.2.14.  Statistical Methods  ................................ ................................ ................................ ......93 
20.3.  Laboratory Ranges Used to Identify Clinically Notable Abnormal 
Laboratory Values  ................................ ................................ ................................ ......93 
20.4.  Vital Signs Values  ................................ ................................ ................................ ......94 
  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276533] OF TABLES  
Table 1:  Abbreviations and Specialist Terms  ................................ ................................ ........... 16 
Table  2: VP-VLY -686-2301 Treatment Arms  ................................ ................................ .......... 26 
Table  3: Schedule of Evaluations  ................................ ................................ ............................. 30 
Table  4: Medications Allowed for Rescue Use  ................................ ................................ ........ 38 
Table 5:  Clinical Laboratory Tests  ................................ ................................ ........................... 48 
Table  6: SAE Criteria and Definitions  ................................ ................................ ...................... 51 
Table 7:  SAE Reporting Information  ................................ ................................ ........................ 55 
Table 8:  Schedule of Evaluations for OLE  ................................ ................................ ............... 74 
Table  9: Schedule of Evaluations for COLE  ................................ ................................ ............ 85 
 
 
 
 
 
 
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276534] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
Table 1: Abbreviations and Specialist Terms  
Abbreviation  Description  
AD Atopic Dermatitis  
AE Adverse Event  
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase (also known as SGPT)  
ANCOVA  Analysis of Covariance  
ANOVA  Analysis of Variance  
AST  Aspartate Aminotransferase (also known as SGOT)  
AUC  Area Under the Plasma  Concentration -time Curve  
AUC 0-∞ Area under the concentration/time curve extrapolated to infinity  
AUC 0-24 Area under the concentration/time curve extrapolated to [ADDRESS_1276535] dosing  
BID Twice a day  
BMI  Body Mass Index  
bpm Beats per Minute  
β-HCG  Beta-Human Chorionic G onadotropin  
BUN  Blood Urea Nitrogen  
C Celsius  
CFR  Code of Federal Regulations  
CINV  Chemotherapy -Induced Nausea and V omiting  
CGI-S Clinician Global Impression of Severity  
CL/F  Oral Clearance  
Cmax The highest observed plasma concentration  
CMH  Cochran -Mantel -Haenszel  
CNS  Central Nerv ous System  
CRF  Case Report Form  
CRO  Clinical Research Organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CV Cardiovascular  
DNDP  Division of Neuropharmacological Drug Products  
dL Deciliter  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
17 
CONFIDENTIAL  Abbreviation  Description  
DNA  Deoxyribonucleic Acid  
DSM -5 Diagnostic and Statistical Manual of Mental  Disorders, F ifth Edition  
EC Ethical Committee  
EC 50 half maximal effective concentration  
EC 90 90 percent effective concentration  
ECG  Electrocardiogram  
EDTA  Ethylenediaminetetraacetic Acid  
e.g. For example  
eCLcr  Estimated Creatinine Clearance  
EOS  End of Study  
ET Early Termination  
FDA  Food and Drug Administration  
g Gram(s)  
GCP  Good Clinical Practice  
GCSDD  Gastroparesis Core Symptom Daily Diary  
GCSI  Gastroparesis Cardinal Symptom Index  
GGT  Gamma -Glutamylt ransferase  
GI Gastrointestinal  
GTBS  Gastroparesis Treatment Benefit Survey  
HDL  High Density Lipoprotein  
HDPE  High -Density Polyeth ylene 
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ID Identification  
i.e. In other words  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IUD Intrauterine Device  
IWRS  Interactive Web Response System  
kg Kilogram  
LDH  Lactate Dehydrogenase  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276536] Level 
OC Observed Cases  
OLE  Open -label Extension  
OTC  Over the Counter  
PAGI -QOL  Patient Assessment of Upper Gastrointestinal Disorder s - Quality of Life  
PAGI -SYM  Patient Assessment of Upper Gastrointestinal Disorders  - Symptom Severity 
Index  
PD Pharmacodynamic  
PE Physical Examination  
PET Positron Emission Tomography  
PG Pharmacogenomic  
pg Pi[INVESTIGATOR_909273]-C Patient Global Impression of Change  
pH Hydrogen ion concentration  
PK Pharmacokinetic  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276537] in the Heart’s 
Electrical Cycle  
RBC  Red blood cell  
REML  Restricted Maximum Lik elihood  
RO Receptor Occupancy  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SGOT  Serum Glutamic -Oxaloacetic Transaminase (also known as AST)  
SGPT  Serum Glutamic Pyruvic Transaminase (also known as ALT)  
SOC  System Organ Class  
SOPs  Standard Operating Procedures  
SP Substance P  
T1/[ADDRESS_1276538]  Upper Limit of Normal  
U.S. [LOCATION_002]  
VAS  Visual Analog ue Scale  
WBC  White Blood Cell  
WHO  World Health Organization  
WOCBP  Women of Childbearing Potential  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
20 
CONFIDENTIAL  3. INTRODUCTION  
This document is a protocol for a human research study.  This study is to be conducted according 
to [LOCATION_002] (U.S.) and international standards of Good Clinical Practice (GCP) (Food and 
Drug Administration [FDA] and International Conference on Harmonization [ICH] guidelines), 
applicab le local  government regulations, and Institutional research policies and procedures.   
 
3.1. Background  
 
Gastroparesis is a chronic disorder characterized by [CONTACT_909337], symptoms associated with gastr ic retention, and absence of  mechanical obstruction  
[1]. The true prevalence of gastroparesis is unknown, but its US prev alence is estimated to be as 
high as 5 million  [2].  The two primary etiologies of gastroparesis are Diabetes Mellitus and 
idiopathic disease together representing over 60% of all cases  [3][4]. Nausea is the most 
commonly reported symptom of gastroparesis, and has been reported in >90% of patients in 
various studies  [5][6].  Vomiting is the second most commonly reported symptom with reports of 
incidence varying between 66 and 88 percent  [5]. Other commonly reported symptoms of 
gastroparesis include early satiety, postprandial fullness, and abdominal pain  [7]. 
 
Despi[INVESTIGATOR_909274], there are 
currently no trea tments for the symptoms of gastroparesis  approved for chronic use .  
Gastroparesis continues to represent a large unmet need.  In a large c ohort study of [ADDRESS_1276539] demonstrated clinically meaningful improvements at 
48 weeks despi[INVESTIGATOR_909275]  [8]. 
 
The mammalian tachykinins (neurokinin [NK]) are a family of peptide neurotransmitters that 
share a common C -terminal sequence. This group includes substance P (SP), neurokinin -A 
(NKA), and neurokinin -B (NKB). SP , the most abundant NK , preferentially binds to the 
neurokinin type -1 (NK-1) receptor and  is involved in the regulation of many physiological 
processes  [9].  NK-[ADDRESS_1276540] distribution in the brain, including the mid -brain, basal ganglia, hypothalamus, 
and limbic system. Neurokinin receptors are also widely distributed in the gut, th e bronchial tree, 
and the vascular system  [10].  
 
Tradipi[INVESTIGATOR_053]  (VLY -686), formerly known as LY686017 , is a potent and selective inhibitor of 
human cell membrane NK -[ADDRESS_1276541] 
pathways of nausea and vomiting are largely undetermined, a definitive role of SP acting at NK -
1 receptors in the nucleus tractus solitarus has been confirmed  [11].  Previous clinical studies 
have demonstrated the efficacy of NK -[ADDRESS_1276542] -operative nausea and vomiting (CINV and PONV)  [12].  
Tradipi[INVESTIGATOR_909276] p atients suffering from gastroparesis.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
21 
CONFIDENTIAL  3.2. Tradipi[INVESTIGATOR_909277] a thorough review, refer to the tradipi[INVESTIGATOR_909278]’s Brochure.  
 
3.2.1.  Nonclinical Pharmacology and Toxicology  
Several in vitro and in vivo safety pharmacology studies (in rodents and dog) were performed to 
assess the effect of tradipi[INVESTIGATOR_909279] (CV), gastrointestinal (GI) , respi[INVESTIGATOR_696], and 
central nervous (CNS) systems. The safety parameters evaluated in these studies were also 
monitored clinically . It was concluded that secondary pharmacological effects related to CNS, 
respi[INVESTIGATOR_696], GI, or CV functioning would not be expected at clinical doses ≤800 mg.  
 
Animal toxicology studies  (a single -dose study in rats; a 13 -week repeat -dose study in mice; 1 -, 
3-, and 6 -month repeat -dose studies in rats; 1 - and 3 -month repeat -dose studies in dogs; a fertility 
and embryo -fetal development study in rats; an embryo -fetal development study in ra bbits; and 
in vitro and in vivo genetic tests)  showed no treatment -related mortality or marked toxicity up to 
and including the no -observed adverse effect level of dosing  (NOAEL) of       1500 mg/kg . 
Tradipi[INVESTIGATOR_909280] 
≤1000 mg/kg. Liver and thyroid enlargement and elevation of serum gamma - 
glutamyl transferase (GGT) were observed in the rat studies and associated with hepatocellular 
hypertrophy and thyroid hyperpl asia, yet t here was no evidence of h epatocellular injury. In the 6 -
month study, these changes were reversible after a 4 -week recovery period. These findings were  
considered secondary to microsomal enzyme induction. In dogs, elevation of serum  alkal ine 
phosphatase (ALP) and alanine aminotransferase (ALT) were observed and  considered 
consistent with hepatic microsomal enzyme induction because they were not  accompanied by 
[CONTACT_909338].  Exposure -based margins of safety for oral administration of 
≤100 mg of tradipi[INVESTIGATOR_909281] 23 -fold and 2.9 -fold, relative to rats after a single dose and 
6 months of treatment, respectively; 40 -fold, relative to mice after 13 weeks of treatment; and 
66-fold, relative to dogs after [ADDRESS_1276543] ing for 
efficacy in chronic pruritus associated with atopic dermatitis.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
22 
CONFIDENTIAL  • Study H8R -EW-HJAC was a dose -escalation study in healthy male subjects designed 
to assess the safety and pharmacokinetics of tradipi[INVESTIGATOR_053] . Doses ranged from [ADDRESS_1276544] notably at doses greater than 30 mg. The oral clearance (CL/F) increased 
with dose level and, in general, the median terminal half -life (T 1/2) was similar across 
all doses, suggesting dose -dependent changes in bioavailability.  
• Study H8R -EW-HJAD was a multiple -dose study with an escalating dosing regimen 
(1, 10, 30, and 100 mg once -daily dosing) over 28 days designed to assess the safety 
and tolerability of  tradipi[INVESTIGATOR_053] . Consistent with the biphasic elimination of tradipi[INVESTIGATOR_053] , 
steady -state was reached within 7 days of daily dosing, and the exposure accumulated 
about 40% relative to a single dose of 1 mg. PET imaging with the 
radiopharmaceutical [11C]GR205171 was used to quantify the relationships between 
oral doses, plasma concentr ation, and the occupancy of cerebral NK-1 receptors by 
[CONTACT_894578][INVESTIGATOR_053] , demonstrat ing a dose - and concentration -dependent increase in frontal 
cortex receptor occupancy (RO). The maximum percent RO was 93% and was 
determined [ADDRESS_1276545] 100 mg dose on Day 28. The RO did not decrease 
substantially from 24 to 72 hours during the w ash-out phase following 100 mg. The 
plasma concentration required to produce half maximal RO (EC 50) and 90% maximal 
RO (EC 90) was estimated to be about 2 ng/mL and 27 ng/mL, r espectively.  
• Study H8R -EW-HJAE was a single -dose, randomized, [ADDRESS_1276546] of a high -fat meal on  the 
pharmacokinetics of tradipi[INVESTIGATOR_053] . Administration of 10 mg of tradipi[INVESTIGATOR_909282] C max and AUC 0–∞ approximately 2 - and 1.5 -fold, respectively, and delayed 
the median T max by 2 hours relative to the fasted state.  
• Study H8R -MC-HJAK was an open -label study in healthy male subjects to assess 
metabolism and disposition of a single oral dose of [14C]VLY -686. It demonstrated 
that tradipi[INVESTIGATOR_909283]. In addition to 
tradipi[INVESTIGATOR_053] , 24 metabolites were detected by [CONTACT_909339]/or by [CONTACT_909340]. Over 13 days, the mean total recovery of 
radioactivity was approximately 88%, with 81% of the dose recovered in feces and 
7% of the dose recovered in urine. Th e fecal profiles showed that a very small 
percentage of excreted radioactivity was due to tradipi[INVESTIGATOR_053] , suggesting that drug had 
been a bsorbed and that its metabolites had been excreted, presumably via the bile.   
• Study H8R -MC-HJAP was performed to characterize any potential PK, 
pharmacodynamic (PD), or adverse eff ect interactions between tradipi[INVESTIGATOR_909284]. Etha nol co -administered with tradipi[INVESTIGATOR_909285] a small but clinica lly irrelevant 
effect on tradipi[INVESTIGATOR_909286] (9.3% increase for C max and 14% increase for AUC 0-24). 
There was no clear or consistent effect of tradipi[INVESTIGATOR_909287] a dose of 50 mg daily 
for 7 days on postural stability or cognition functions compared to placebo and no 
clear or consistent adverse int eraction effects between tradipi[INVESTIGATOR_909288]. Overall, there was no 
indic ation in this study that tradipi[INVESTIGATOR_909289] 50 mg daily for 7 days had an 
adverse PK or PD interaction with ethanol.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
23 
CONFIDENTIAL  • Study VP -VLY -686-[ADDRESS_1276547]-dose.  Therefore, AUC0 -∞, T1/2 and λZ could not be calculated.  In general, the 
PK characteristics for VLY -686 observed in this study were similar to those observed 
in Study H8R -EW-HJAC.   
• Study VP -VLY -686-[ADDRESS_1276548] on the CYP3A4/5 enzyme.   Overall, 
the study data indicate that  repeated oral doses of 85 mg tradipi[INVESTIGATOR_909290] 
Q12H is generally safe and well -tolerated in male and female healthy subjects.  
• Study VP -VLY -686-2101 was a  proof of concept study conducted in atopic 
dermatitis patients with chronic pruritus.  Although a statistically significant 
difference from placebo was not seen in the overall intent to treat population, a 
PK/PD correlation was demonstrated in the tradipi[INVESTIGATOR_909291].  Based on this 
PK analysis, individuals with higher tradipi[INVESTIGATOR_909292] a statistically and clinica lly meaningful difference from placebo as 
measured on a 100  mm Visual Analog Scale (VAS) for itch.  
• Study VP -VLY -686-[ADDRESS_1276549] itch and 
disease severity in patient s with atopic dermatitis.  
• Study VP -VLY -[ADDRESS_1276550] itch in 
patients treated with tradipi[INVESTIGATOR_909293] 8 week period of 85 mg BID dosing 
compared t o placebo in 300 patients.  
 
In clinical studies , tradipi[INVESTIGATOR_909294] a single dose up to 800 mg, up to 12 days 
at a daily dose of 170 mg, and up to 4 weeks at a daily dose of 100 mg.  Following 12 days of 
twice daily 85 mg tradipi[INVESTIGATOR_909295] 24 healthy volunteers, the median time to 
maximum plasma concentration ranged from 2 to 6 hours and the geometric mean (%CV) 
elimination half -life was 34 (41%) hours.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
24 
CONFIDENTIAL  4. TRIAL OBJECTIVES AND RATIONALE  
4.1. Objectives  
4.1.1.  Primary  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909296].   
 
4.1.2.  Secondary  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909297]  
• To evaluate  the efficacy of tradipi[INVESTIGATOR_909298]  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909299]  
• To explore the safety and tolerability o f multiple oral doses of tradipi[INVESTIGATOR_053] . 
 
4.1.3.  Exploratory  
• To identify genetic markers that correlate with response to tradipi[INVESTIGATOR_909300].  
• To identify genetic markers that correlate with adverse events that may occur upon 
treatment with tradipi[INVESTIGATOR_053].  
• To identify genetic markers that are associated with gastroparesis and/or gastroparesis 
symptoms and diseases associated with NK -1 receptors.  
• To identify genetic markers that are associated in the metabolism, distribution, and/or 
excretion of tradipi[INVESTIGATOR_181937].   
 
4.2. Rationale  
4.2.1.  Study Rationale  
The underlying pathophysiology of gastroparesis is complex and remains largely unknown.  
Prokinetic therapy has been the traditional mainstay of gastroparesis treatments, but studies 
continue to demonstrate a lack of correlation between reduction in gastric emptying delays and 
relief of gastroparesis symptoms [5]. 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276551] therapy in severe, 
refractory gastroparesis cases  [13][14].  Thus, NK -1 receptor antagonists, like tradipi[INVESTIGATOR_053] , are 
promising potential the rapeutics for treating nausea associated with gastroparesis.  
 
4.2.2.  Rationale for Dose  and Study Design  
In a multiple -dose PET clinical study , frontal cortex r eceptor occupancy was recorded at 93% 
following 7  days of 100 mg daily dosing.  Based on the PET study findings, it is estimated that a 
dose of approximately 85 mg daily would achieve 90% brain receptor occupancy [ADDRESS_1276552] 
steady -state dosing.  A target brain NK -1 receptor occupancy of 90% is based on a published 
study comparing the efficacy of two different doses in aprepi[INVESTIGATOR_053], an NK -[ADDRESS_1276553] was observed at a dosing regimen 
which reached 90% receptor occupancy than a dosing regimen reaching 80% receptor occupancy 
[12].   
 
While it is hypothesized that a daily dose of [ADDRESS_1276554] a peripherally -mediated 
component involving modulation of abdominal vagal afferent  activity  [15].   Additionally, the 
pharmacokinetic profile of tradipi[INVESTIGATOR_909301] -exposure relati onship seen in healthy volunteers.  These two factors 
lead to the possibility that a higher daily dose of tradipi[INVESTIGATOR_909302], a more frequent dosing regimen may be warranted.  As [ADDRESS_1276555] 85 mg 
BID and matching placebo.   
 
The completed nonclinical and clinical safety studies with tradipi[INVESTIGATOR_909303] a favorable safety 
profile. Clinical laboratory tests, vital signs, 12 -lead ECG, and physical examination (PE) data 
showed no clinically significant alterations due to administra tion of tradipi[INVESTIGATOR_053].  Additionally, 
preclinical studies showed no evidence of a drug -related QT prolongation.  
 
4.2.3.  Risk and Benefit  
The potential benefit for su bjects, if randomized to tradipi[INVESTIGATOR_053] , is the possib ility of experiencing 
decreased symptoms of gastroparesis while participating in this study.  Nonclinical and clinical 
data to date have not indicated any likely toxicity at doses to be used in this study, and the drug 
has been well -tolerated in previous clinical studies.  The most commonly reported adverse events 
(≥ 2% and 1.25x placebo) in previous clinical studies were somnolence, dizziness, fatigue, and 
dry mouth.  Nonetheless, as tradipi[INVESTIGATOR_909304], there may be unforeseen 
risks associated with its use.   
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
26 
CONFIDENTIAL  5. INVESTIGATIONAL PLAN  
5.1. Overall Study Design and Plan: Description  
This is a randomized , double -blind , placebo -controlled study to be conducted in the United 
States . Approximately o ne hundred fifty (150) patients diagnosed with gastroparesi s of either 
diabetic or idiopathic origin  satisfying the selection criteria for the study will be randomized 1:1  
to tradipi[INVESTIGATOR_909305]  (Table  2). Randomization will be stratified by 
[CONTACT_522476] (idiopathic or diabetic), and enrollment for each etiology will be capped at 60% 
of the total sample size.  
 
Table  2: VP-VLY -686-2301 Treatment Arms  
Arm  Total Daily Dose  AM Dose  PM Dose  
Tradipi[INVESTIGATOR_909306]  170 mg  85 mg tradipi[INVESTIGATOR_053]  85 mg tradipi[INVESTIGATOR_909307]  0 mg  Placebo  Placebo  
 
The study is divided into four phases: the screening  phase , the evaluation phase , the open label 
extension phase , and the continued open label extension phase . The screening phase includes 
screening and baseline visits where eligibility for the study will be assessed. The evaluation 
phase includes 4  weeks of placebo -controlled, double -blind , randomized treatment. Daily diaries 
will be collected throughout both phases of the study. At the end of the 28 -day evaluation  phase, 
those subjects who completed this phase enroll into an 8-week open -label extension (OLE) 
where each subject will receive the same dose of tradipi[INVESTIGATOR_909308] ( 85 mg  bid, approximately 12 hours apart) . Subjects  who complete the 8 week open 
label phase can return and enroll into a 52 -week continued open label extension phase (COLE).  
 
5.1.1.  Screening Phase  
The screening  phase includes the screening and baseline visits. Informed consent must be 
obtained prior to the initiation of any study related screening procedures.   The screening phase 
will be at least [ADDRESS_1276556] of assessments performed at each visit are listed in Table  3 and Section  9. 
 
[IP_ADDRESS].  Screening Visit  (Visit 1)  
During the Screening Visit  (Visit 1) , safety and efficacy assessments  will be performed  to assess 
the subject’s initial eligibility after the subject  signs the informed consent  form .  Collection of 
adverse event information will begin at the time the ICF is signed.   Subjects wi ll be trained and 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276557] the results of the study, inclusion 
criteria 2d and 2e should NEVER be shared with subjects or potential subjects .  
The Screening Visit may be repeated following medication washout and prior to baseline diary 
collection at the discretion of the Investigator and/or Medical Monitor.   
Subjects who do not meet eligibility criteria will be considered screen failures.  Screen failures 
may be given the opportunity for reconsideration at a later time (re -screening) at the discretion of 
the Investigator  and approval by [CONTACT_1034].  
 
[IP_ADDRESS].1.  Visit [ADDRESS_1276558] evaluation that 
demonstrates delayed gastric emptying that is outside the 10 -year window can still be considered 
as symptomatically suffering from gastroparesis and scheduled for a Visit 1 provided they meet 
all other Visit 1 criteria, including:  
-history of nausea for the past [ADDRESS_1276559] meets all other criteria (including moderate to high 
nausea on mGCSI as determined by a score of ≥ 3), the subject may begin completing their daily 
diary according to the normal screening process described in S ection [IP_ADDRESS].  
The subject will also be scheduled to return for an unscheduled visit to take place within [ADDRESS_1276560]’s objective evidence of delayed gastric emptying . The choice of utilizing breath test or 
scintigraphy will be at the investigator’s discretion. If this test confirms delayed gastric 
emptying, the subject will continue participation in the study according to the normal screening 
procedures. Subjects whos e test does not confirm delayed gastric emptying will be considered 
screen failures.  
 
[IP_ADDRESS].  Baseline Visit (Visit 2)  
On Day 0  (Visit 2/Baseline) , assessments will be performed and diary data will be reviewed to 
assess the subject’s continued eligibility. Subjects continuing to meet all eligibility criteria will 
be randomized to one of two treatment arms ( Table  2), and will be given enough study 
medication to  last until the next visit.  Study staff should be careful to review eligibility criteria 
that is specific to the Baseline Visit including diary review to determine eligibility based on 
symptom severity.  Subjects must have at least 24 daily screening diary entries prior to 
randomization.  The screening may be extended for a total of up to 35 days to accommodate this. 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
28 
CONFIDENTIAL  Subjects  who are randomized will be instructed to begin taking study medication in the evening 
of Day 0  (Baseline/Visit 2).  Twice daily dosing will begin the day following the baseline visit.  
 
5.1.2.  Evaluation Phase  
[IP_ADDRESS].  Visit [ADDRESS_1276561] s will return to the clinic on Day  14 (± 3 days) for Visit [ADDRESS_1276562] until Visit 4.  
 
[IP_ADDRESS].  End of Phase or Early Termination  (Visit 4 ) 
At the End of Study Visit (Day 28  ± 3 days) or at the time of early termination , subjects will 
return to the clinic for safety and efficacy assessments.  Diary and medication compliance will be 
reviewed.  
 
5.1.3.  Open -Label Extenion Phase  
 All subjects who compl ete the short -term double -blind  phase will continue treatment with 
tradipi[INVESTIGATOR_909309] [ADDRESS_1276563] previously completed this study can come back to for visit COLE -V1-B to allow all 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
29 
CONFIDENTIAL  original V1 screening labs and other safety assessments as well as the continued open label 
informed consent to be collected prior to COLE dosing.  
A detailed description of this COLE phase can be found in  Appendix  20.2  
 
   
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
30 
CONFIDENTIAL  Table  3: Schedule of Evaluations  
Visit  V1 
Screening  V2 
Baseline  V3 
 V4 
EOP  
Study Day  ≥28 days prior 
to Day 0  Day 0  Day 141 Day 281  
Informed Consent Form (ICF)  [ADDRESS_1276564] demography and medical history  X    
Prior/concomitant medications  X X X X 
Adverse Event (AE) Query3 X X X X 
Collection of menstrual cycle information  X X X X 
Serum β -HCG (for WOCBP)  X   X 
Urine pregnancy test (for WOCBP)   X X  
TSH , T4 X X X X 
Urine D rug Screen  X X X X 
HbA1c, h ematology, chemistry, and urinalysis  X X X X 
Pharmacogenomic (PG) sample   X   
Pharmacokinetic (PK) sample   X X X 
12-lead resting ECG  X X X X 
Vital signs and body measurement s4 X X X X 
Physical Examination (PE)  X   X 
C-SSRS5 X X X X 
mGCSI6 & mPAGI -SYM  X X X X 
Gastroparesis Treatment Benefit Survey (GTBS)  X    
PAGI -QOL   X  X 
Patient Global Impression of Change (PGI -C)   X X 
Clinical Global Impression of Severity (CGI -S)  X X X 
Randomization   X   
Study medication dispensation   X X X 
Study medication collection & compliance    X X 
Subject diary instruction  X    
Subject diary review   X X X 
EOP     X 
Gastroparesis Core Symptom Daily Diary  (GCSDD)                                                                  
1 within +/ - 3 days  
2 Informed consent will be obtained prior to the performance of any study procedure(s)  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
31 
CONFIDENTIAL  3 Adverse event collection will begin at the time the ICF is signed.  
4 Vital sign collection at all visits. Height collection at V1. Body weight collection at V1, V2, and V4.  
5 The Screening/Baseline C -SSRS will occur at V1.  The Since Last Visit C -SSRS will occur at all other visits.  
6 mGCSI questions on symptom changes  (Part II) will only be administered at V3 and V4.   
EOP= End of Phase; ; WOCBP = Women of Child -bearing Potential; ECG = electrocardiogram; C -SSRS = 
Columbia Suicide Severity Rating Scale; mGCSI = modified Gastroparesis Cardinal Symptom Index; PAGI -QOL = 
Patient Assessment of Upper Gastrointestinal Symptoms – Quality of Life  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276565] s will be considered eligible for participation in the study  if the following criteria are 
satisfied:    
1. Male and female subjects aged 18 – 70 years (inclusive);  
2. Diagnosed with idiopathic or diabetic gastroparesis  with moderate to severe na usea:  
a. Demonstrated delayed gastric emptying of a solid meal via either scintigraphy or 
gastric breath te st within [ADDRESS_1276566] 24 screening diary entries,  
NOTE:  CRITERIA 2D-E ARE CONFIDENTIAL AND SHOULD NOT BE SHARED 
WITH SUBJECTS, POTENTIAL SUBJECTS, OR ANYONE OUTSIDE OF THE 
IMMEDIATE STUDY TEAM.  
d. mGCSI individual nausea score ≥ 3 at Visit 1,  and 
e. Average daily diary nausea severity ≥ [ADDRESS_1276567] 50% days of nausea 
during the screening period;  
3. Patient’s gastroparesis symptoms persist despi[INVESTIGATOR_522463]/or life -style modifications ; 
4. Body Mass Index (BMI) of ≥18 and ≤38 kg/m2 (BMI = weight (kg)/ [height (m)]2);  
5. Subjects must agree to the following study restrictions:   
a. Males of procreative capacity (not surgically sterile) will use an acceptable method 
of contraception from randomization through [ADDRESS_1276568] -menopausal  partner;   
b. Females of child -bearing potential (not surgically sterile or post -menopausal, 
defined as 12 months without menses) will use an acceptable method of 
contraception f rom 1 month prior to randomization (or screening, if earlier) through 
[ADDRESS_1276569] dose of study medication. Examples of acceptable 
methods of contraception for females include abstinence, double barrier method, 
IUD, hormonal contraception, or sterilized partner;  
6. Ability and acceptance to provide written informed consent;  
7. Willing to partici pate in the pharmacogenomic sample collection ; 
8. Willing and able to com ply with all study requirements  and restrictions , including but not 
limited to:   
a. Daily symptom diary completion ,  
b. Prohibited medications , and  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276570] control of blood glucose  (T1DM and T2DM patients ); 
9. Willing to not participate in any other interventional trial for the duration of their 
participation.  
 
6.2. Subject Exclusion Criteria  
Subjects will be excluded from the study if any of the following criteria apply:  
1. Another active disorder or treatment which could explain or contribute to symptoms in 
the opi[INVESTIGATOR_689] (including but not limited to gastric malignancy, 
neurological disorder, or heavy doses of strong anticholinergics);  
2. Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, post -surgical 
cause of gastroparesis, or gastric stimulation device surgically implanted within the last 
year or if implanted more than a year ago, have changed stimulation settings wi thin the last 
3 months (ie gastric stimulation device must have a stable setting for at least 3 months);  
3. Gastric or  parenteral feeding  within 4 weeks of screening ;  
4. Pregnancy or nursing;  
5. History of intolerance and/or hypersensitivity to medications similar to tradipi[INVESTIGATOR_522465];  
6. History (including family history) or current evidence of congenital long QT syndrome or 
known acquired QT interval prolongation  (including QTc > 450 in males or > 470 in 
females  at screening ); 
7. History of suicide attempt and/or suicidal ideation (of type 4 or 5 on the Columbia Suicide 
Severity Rating Scale (C -SSRS)) within [ADDRESS_1276571] is at risk of suicide 
at Screening or Baseline, in the opi[INVESTIGATOR_871];  
8. History of an eating disorder within 2 years of screening;  
9. Recent history (within six months of screening) of Alcohol Use Disorder or Substance Use 
Disorder as defined in DSM -5 or evidence of such abuse which may include a positive 
drug screen at the Screening visit;  
10. Uncontrolled thyroid disease;  
11. Unstable cardiac, respi[INVESTIGATOR_696], hepatic or renal disease ; 
12. Evidence of uncontrolled blood glucose (including HbA1C >[ADDRESS_1276572] 
60 days);  
13. Indication of impaired liver function (including values for AST, ALT, or bilirubin > 1.5 
times the Upper Limit of Normal, unless isolated bilirubin > 1.[ADDRESS_1276573] due solely to 
Gilbert’s syndrome);  
14. Has a creatinine level > 1. 5x ULN;  
15. Use of prohibited  medication (Section  7.2.1 ) or medication wit h anti -nausea, antiemetic, 
neuro modulating, or prokinetic effect within 2 weeks of the screening visit EXCEPT  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
34 
CONFIDENTIAL  when administered on a stable daily dosing schedule (stable for at least 3 months prior to 
the screening visit) or administered under protocol -specified rescue medication 
guidelines;  
16. Use of the following within 2 weeks of screening: another  NK-[ADDRESS_1276574], p henergan more than 2 times per day, or opi[INVESTIGATOR_909310] 
2 times per week;   
17. Pyloric injection of neurotoxins (e.g. botulinum type A or B) within 3  months of the 
Screening Visit;  
18. Exposure to any investigational medication, including placebo or domperidone, within 60 
days of the Baseline Visit;   
19. Anyone affiliated with the site or sponsor and/or anyone who may consent under duress;  
and  
20. Any other reason as determined by [CONTACT_894577] -
benefit of study participation, may interfere with study compliance, or may confound study 
results.  
 
6.3. Subject  Withdrawal Criteria  
The term “discontinuation” refers to the randomized subject ’s premature withdrawal from the 
study before completing all scheduled evaluations.  
 
Subject s may voluntarily withdraw from the study at any time for any reason. Subjects may also 
be discontinued from the study for any of the following reasons:  
• If in the Investigator’s judgment, continuation in the study may prove harmful to the 
subject .  Such a decision may be precipi[INVESTIGATOR_152208], including changes in 
vital signs, physical examination, ECG, or laboratory tests.  The Investigator will 
maintain autonomy in making medical/safety decisions regarding the subject ’s 
continued participation in the trial.  Clinically notable abnormalities in vital signs or 
laboratory tests are provided in Appendices  Section  20.[ADDRESS_1276575] ’s continued participation;  
• Noncompliance;  
 
For subjects withdrawing from the study prematurely, all efforts wil l be made to perform the 
Visit 4  Early Termination procedures.  
 
Documented reason:   It will be documented whether or not each subject  completed the clinical 
study.  For subjects who do not complete the clinical study, the primary reason for 
discontinuation will be documented in the CRF.  Possible  reasons for discontinuation include:  
1. Protocol deviation  (including noncomp liance to study requirements ) 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
35 
CONFIDENTIAL  2. Adverse event(s)  (including abnormal laboratory values, and abnormal test procedures)  
3. Pregnancy  
4. Lost to follow -up 
5. Death 
6. Subject  withdrew consent  
7. Unsatisfactory therapeutic effect  
8. Other (specify) . 
 
Subject s who discontinue because of an AE, abnormal laboratory value, or abnormal test result 
will be followed until resolution or for 30 days, whichever is less. Events which are stable after 
30 days will not require additional follow up.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276576] S – EVALUATION  PHASE  
7.1. Study Medication  
7.1.1.  Dosing  
Randomized s ubject s will be dispensed stu dy medication under double -blind  conditions .  Each 
subject will be dispensed one bottle of study medication at Visit [ADDRESS_1276577] 
capsule can be identified in the emesis, a second capsule should be administered .   
 
7.2. Concomitant Medications  
The administration of concomitant medication (including OTC medication) will be clearly 
documented on the concomitant medication CRF page.   
In general, concomitant medications that  may interfere with the assessment of th e efficacy 
and safety of tradipi[INVESTIGATOR_909311] .  
Prohibited  medications and treatments are prohibited from the screening visit (or 4 weeks prior 
to the Randomization Visit  when a washout is required ) through the end of study participation. 
Questions regarding the use of concomitant medications not listed should be directed to the 
Medical Monitor.  
 
7.2.1.  Prohibited Medications  
The following medications are prohibited from use during the screening and treatment periods of 
the study . This list is not exhaustive.  In the event that a study subject is on any medication or 
treatment that is not listed but that may interfere with the assessment of the efficacy and safety of 
tradipi[INVESTIGATOR_053], the eligibility of the subject and/or use of the po tential medication should be reviewed 
with the Medical Monitor and the Sponsor  
• NK-1 antagonists (including but not limited to aprepi[INVESTIGATOR_053], netupi[INVESTIGATOR_053], rolapi[INVESTIGATOR_053])  
• Second generation 5 -HT3 antagonists (including palonosetron)  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
37 
CONFIDENTIAL  • Any medication with anti -nausea,  antiemetic, neuro modulating, or prokinetic effects 
that is not taken on a stable daily dosing schedule (stable for at least 3 months prior to 
the screening visit) is prohibited from the screening visit through the end of study 
with the exception of protocol -defined rescue medication defined in Section  7.2.2 . 
• Phenergan (or promethazine ) administration more than 2 times per day  or Phenergan 
use that is not considered rescue use.  
• Opi[INVESTIGATOR_909312] 2  times per week.  
• Marijuana (illicit or medical) use (including a positive drug screen for marijuana )  
 
The following medications are prohibited from use beginning one week before randomization 
through the end of the treatment perio d: 
• Drugs with a narrow therapeutic index: carbamazepi[INVESTIGATOR_050], cyclosporine, digoxin, 
ethosuximide, lithium, phenytoin, procainamide, quinidine, sirolimus, tacrolimus, 
theophylline, warfarin  
• Strong CYP3A4 inhibitors (listed by [CONTACT_71963]):  
Class  Prohibited medications  
Antibiotics  clarithromycin, telithromycin  
Antifungals  itraconazole, ketoconazole, posaconazole, voriconazole  
Antivirals  boceprevir, indinavir, lopi[INVESTIGATOR_054], nelfinavir, ritonavir, saquinavir, telaprevir, 
topi[INVESTIGATOR_909313]  
 
7.2.2.  Rescue Medication  
Anti-nausea  or antiemetic  medication that is not administered on a stable daily dosing regimen is 
considered rescue medication . Patients may use  rescue medicatio n per the Rescue Medication 
Guidelines.  
 
[IP_ADDRESS].  Rescue Medication G uidelines  
1. Only medications listed in Table  [ADDRESS_1276578] previous experience with use of the medication.  
3. Rescue medication administration sh ould be documented in the patient diary  
4. Patient use of rescue medication w ill be reviewed at study visits  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
38 
CONFIDENTIAL  Table  4: Medication s Allowed for Rescue Use  
The following medications are allowed for rescue use  
ondansetron , prochlorperazine, promethazine  
7.2.3.  Medication Washout  
In the event that a medication washout period is required, Visit [ADDRESS_1276579]  be recorded on the overdose CRF . An 
overdose (intentional or accidental) is defined as the following:  >3  capsules of double -blind 
study medication taken within a 24-hour period  (except when re -administered within the 
guidance of Section  7.1.2 ). 
 
7.4. Treatment Assignment  
7.4.1.  Subject ID Assignment  
Subject  Identification (ID)  - Each subject  who signs an informed consent form should receive a 
subject  identification number.  The subject  identification number (ID) consists of a 3 -digit site 
number (Site No.) and a [ADDRESS_1276580]  number ( Subject  No.).  The Site No. and Subject  No. will 
be separated by a hyphen.  
 
Site No.  - Vanda (or designee) will assign a unique, three -digit number to the site. 
 
Subject  No. – Subject numbers will be assigned to each subject  starting with 1001 (i.e. 1001, 1002, 
1003 …) . The ID for a subject  who discontinues from the study for any reason after having been 
assigned an ID will not be reassigned.   
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276581] will be assigne d. 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276582] gelatin capsules provided as a strength of 85  mg. 
The 85 mg capsule formulation also contain s spray -dried lactose  monohydrate , microcrystalline 
cellulose (Avicel PH102 and PH200), povidone, croscarmellose sodium, sodium lauryl sulfate, 
and magnesium stearate as excipi[INVESTIGATOR_840]. Placebo  capsules will be provided in size and appearance 
identical to those containing tradipi[INVESTIGATOR_053] .  
 
8.2. Study Medication  Packaging and Labeling  
Medica tion labels will comply with US regulations . The st orage conditions for the study 
medication  will be described on the medication label.  
 
Study  medication  capsules will be provided in high -density polyethylene (HDPE) bottles with a 
child -resistant cap  containing desiccant . Each bottle  will contain [ADDRESS_1276583] until the next visit (one bottle will be 
dispensed at Visit 2 and collected at Visit 3, a second bottle will be dispensed at Visit 3 and 
collected at Visit 4). Subjects should be instructed to bring the study medication bottle along 
with any unused capsu les to the sit e at his/her next visi t.  Each bottle will have a two -part label.  
The second part of the label will be attached to the subject’s source documents before the bottle 
is dispensed to the subject.  
 
8.3. Study Medication  Storage  
Study medication  should be stored at  20-25 °C with excursions permitted to 15 -30 °C.  Capsules 
should not be crushed or broken, but should be swallowed whole.  Study medication  will be 
dispensed to only randomized subject s at the study site.   
 
8.4. Study Medication  Accountability  
Vanda Pharmaceuticals Inc. is responsible for assuring that the quality of the study medication  is 
adequate for the duration of the study.  
 
Study medication should be used in accordance with the protocol, under the supervision  of the 
Investigator or delegated by [CONTACT_909341] .   
 
The Investigator or designee is responsible for logging receipt of each shipment of study 
medication, confirming the actual shipment contents, and in dicating the status of each bott le.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276584] comply with applicable regulations and guidelines, and should 
include:  
• Amount of study medication  received  
• Medication bottle number  
• Dates of medication  inventory movement  
• Amount dispense d 
• Initials of person responsible for each medication  inventory entry  
 
Accurate recording of all study medication administration (including dispensing and dosing) will 
also be made in the appropriate sec tion of the subject ’s CRF and source documents.  
 
Vanda or its designee will instruct the Investigator on the return or destruction of unused study 
medication.  If any study medication was lost or damaged, its disposition should be documented 
in the subject ’s source documents as well as the drug accountability record.  Study medication 
supplies will be retained at the clinical site until instructions for return or destruction of the 
supplies are received from Vanda or its designee.  
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
42 
CONFIDENTIAL  9. STUDY ASSESSMENTS – EVALUATION PHASE  
9.1. Study Assessments per Visit   
9.1.1.  Screening Visit (Visit 1 ) 
The following will be performed after the subject signs the informed consent form:  
• Review of inclusion/exclusion criteria  
• Collection of demographic information, medical history, and prior and concurrent 
medications;  vi tal sign and body measurements  
• Physical examination (PE) (excluding genitourinary examinatio n unless clinically 
indicated)  
• ECG  
• Screening/Baseline C -SSRS questionnaire  
• Clinical laboratory assessments: hematology, chemistry  (including estimated 
creatinine clearance (eCLcr; based on the Cockcroft -Gault equation) , urinalysis, 
HbA1c, thyroid stimulating hormone  (TSH) , thyroxine (T4) , urine drug screen,  
• Serum pregnancy test and collection of menstrual cycle information (for females o f 
child -bearing potential)  
• Modified Gastroparesis  Cardinal Symptom Index (mGCSI)  Part I  
• Modified PAGI -SYM (mPAGI -SYM)  
• Gastroparesis Treatment Benefit Survey (GTBS)  
Collection of adverse event information will begin at the time the ICF is signed.  Subjects will be 
given a diary and instructed to begin completing the screening portion of their diary for at least 4 
weeks prior to the baseline visit.   Diary data will be  assessed at Visit 2 to confirm patient 
eligibility for randomization (see Section  6.1). 
 
9.1.2.  Baseline Visit (Visit 2, Study Day 0)  
On Day 0  (Visit 2/Baseline) , the following assessments will be performed to assess the subject’s 
continued eligibility:  
• Review of inclusion/exclusion criteria  
• Adverse event query  
• Collection of conc omitant  medications   
• vital sign s and weight measurements  
• Since last visit C -SSRS   
• Urine pregnancy test and collection of menstrual cycle information (for fema les of 
child -bearing potential)  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
43 
CONFIDENTIAL  • Gastroparesis Core Symptom Daily Diary (GCSDD) review : To be considered eligible 
for randomization, s ubjects must:  
− meet diary eligibility criteria  (Section  6.1 )  
− have at least 24 daily diary entries  
− have a daily diary completion rate ≥ 24/35 (68%)  
 
Individuals continuing  to meet eligibility criteri a will be randomized, and t he following 
assessments will also be performed during this visit:  
• ECG;  
• Clinical laboratory assessments (HbA1C, hematology, chemistry  (including e CLcr; 
based on the Cockcroft -Gault equation ), urinalysis , thyroid stimulating hormone 
(TSH), thyroxine (T4), and urine drug screen ) 
• PG sample  
• Baseline Pharmacokinetic (PK) sample  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  Part I  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Assessment of Upper Gastrointestinal Disorder  Quality of Life (PAGI -QOL)  
• Clinical Global Impression of Severity (CGI -S) 
• Study medication  instruction and dispensation (first dose will be administered on 
evening of Day 0)  
 
9.1.3.  Visit 3  (Study Day 14 ±  3 days)  
• Urine pregnancy test and collection of menstrual cycle information ( for females of 
child -bearing potential)  
• Pharmacokinetic  (PK)  sample  
• Semi -supi[INVESTIGATOR_050] r outine v ital signs (body temperature, respi[INVESTIGATOR_697], blood pressure, and 
pulse)   
• ECG  
• Clinical laboratory assessments (HbA1C, hematology, chemistry  (including e CLcr; 
based on the Cockcroft -Gault equation ), urinalysis , thyroid stimulating hormone 
(TSH), thyroxine (T4), and urine drug screen ) 
• Adverse Event query  
• Concomitant medication  review  
• Since last visit C -SSRS  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
44 
CONFIDENTIAL  • Diary review  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Global Impression of Change (PGI -C) 
• Clinical Global Impression of Severity (CGI -S) 
• Study medication co llection and review  
• Study medication instruction and dispensation  
 
9.1.4.  Visit 4  (Study Day 28  ± 3 days)   
• Full PE (excluding pelvic, rectal and breast examinations unless clinically indicated)  
• Laboratory evaluations ( HbA1C, hematology, chemistry  (including e CLcr; based on 
the Cockcroft -Gault equation ), urinalysis , thyroid stimulating hormone (TSH), 
thyroxine (T4), and urine drug screen ) 
• Serum pregnancy test and collection of menstrual cycle information (for females of 
child -bearing potential)  
• Pharmacokinetic blood sample   
• ECG  
• Semi -supi[INVESTIGATOR_050] r outine vital signs (body temperature, respi[INVESTIGATOR_697], blood pressure, and 
pulse)  and weight   
• Adverse Event query  
• Concomitant medication  review  
• Since last visit C -SSRS  
• Review diary 
• Collect diary 
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Global Impression of Change (PGI -C) 
• Patient Assessment of Upper Gastrointestinal Disorder  Quality of Life (PAGI -QOL)  
• Clinical Global Impression of Severity (CGI -S) 
• Study medication collection and review  
• Recor ds EOP  
• Review of Inclusion criteria (only for subjects that are continuing  to the OLE phase)  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
45 
CONFIDENTIAL  • Dispense Study Drug (only for subjects that are continuing to  the OLE phase)  
 
9.1.5.  Unscheduled Visits 
Unscheduled visits may be performed at any time at the discretion of the Investigator.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
46 
CONFIDENTIAL  10. ASSESMENTS O F EFFICACY  
The following rating scales will be used in this study to assess efficacy:  
• Gastroparesis Core Symptom Daily Diary (GCS DD) 
• Modified Gastroparesis Cardinal Symptom  Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Global Impression – Change (PGI -C) 
• Patient Assessment of Upper Gastrointestinal Disorders – QOL (PAGI -QOL)  
• Gastroparesis Treatment Benefit Scale (GTBS)  
• Clinician  Global Impression – Severity (CGI -S) 
 
10.1. Patient Reported Outcome (PRO) Assessments  
10.1.1.  Gastroparesis Core Symptom Daily Diary (GCSDD)  
Subjects will complete a daily symptom questionnaire at least [ADDRESS_1276585]-prandial fullness, bloating, and abdominal pain will be rated by [CONTACT_909342] a Likert  scale 
from 0 = none to  5 = very severe.  The frequency of vomiting , duration of nausea, and the use of 
rescue medication will also  be collected .  
 
10.1.2.  Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
The modified Gastroparesis  Cardinal Symptom Index is a patient reported outcome administered 
in-clinic with a 2 -week recall period.  Part I of the questionnaire consists of the traditional GCSI 
and severity rating of upper abdominal pain as well as severity of overall symptoms. The 
questionnaire uses the same 0 -5 scale utilized in both the GCSI  and the PAGI -SYM  [16].    Part 
II of the questionnaire will be administered at post -treatment visits (Visit 3 and Visit 4), and uses 
a 7-point rating scale for the subject to rate their own improvement in their core gastroparesis 
symptoms relative to baseline.  Symptoms are rated as: 1, very much improved; 2, much 
improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very 
much worse.   
10.1.3.  Modified Patient Assessment of Gastrointestinal Disorders – Symptoms 
(mPAGI -SYM ) 
The modified PAGI -SYM is a patient reported outcome administered in -clinic with a 2 -week 
recall period. This questionnaire will include PAGI -SYM items not included in the mGCSI. The 
questionnaire uses the same 0 -5 scale utilized in both the GCSI and the PAGI -SYM [16].    
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
47 
CONFIDENTIAL  10.1.4.  Patient Global Impression -Change  (PGI -C) 
The P GI-C is a [ADDRESS_1276586] rates their own improvement in overall 
symptoms relative to the baseline assessment. It is rated as: 1, very much improved; 2, much 
improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very 
much worse.  
 
10.1.5.  Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life (PAGI -
QOL)  
The 30 -tem Patient Assessment of Upper Gastrointestinal  Disorders -Quality of Life (PAGI -
QOL©) questionnaire is a valid and reliable instrument assessing quality of life in patients with 
gastroparesis. The questionnaire cover s five domains: Daily Activities, Clothing, Diet and Food 
Habits, Relationship, and Psychological Well -Being and Distress  [16].  Affect to overall quality 
of life and well -being over the past two weeks is rated on a scale of 0 = “None of the time” to 5 = 
“All of the time” for each item.  
 
10.1.6.  Gastr oparesis Treatment Benefit Survey  (GTBS)  
The Gastr oparesis Treatment Benefit Survey  (GTBS) is administered prior to the initiation of 
therapy.  The GTBS requires the subject to rate the relative importance of the relief of each of 
the core symptoms from  0 = ‘not at all important’ to 4 = ‘very important’. The GTBS is 
designed to be used in conjunction with Gastroparesis Core Symptom Daily Diary (GCSDD) 
data to provide symptom -specific and overall benefit scores which place higher weight on the 
relief of symptoms most important to the individual patient.  
 
10.2. Clinician Global Impression of Severity (CGI -S) 
The CGI -S is a 7 -point scale in which the clinician rates the severity of the patient's illness at the 
time of assessment, relative to the clinician's past experience with patients who have the same 
diagnosis. Considering total clinical experience, a patie nt is assessed on severity of illness at the 
time of rating 1: normal, not at all ill; 2: borderline ill; 3: mildly ill; 4: moderately ill; 5: 
markedly ill; 6: severely ill; or 7: extremely ill.  
 
10.3. Pharmacokinetic Assessment  
A single blood sample will be collected  at each visit as a secondary measure of overall study 
medication compliance. Samples will be tested for plasma concentrations of tradipi[INVESTIGATOR_909314].  Pharmacokinetic analyses may be provided in a separate report.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
48 
CONFIDENTIAL  11. ASSESSMENT OF SAFETY  
11.1. Safety Parameters  
Safety assessments should be conducted as specified in the Schedule of Evaluations ( Table  3). 
These assessments include: the regular monitoring and recording of all AEs and serious adverse 
events ( SAEs ); regular monitoring of hematology, blood chemistry and urinalysis values , vital 
signs , body measurements and suicidal ideation and behavior ; and the performance of physical 
examinations and electrocardiograms.  Any amendments to this protocol that change the 
schedule of visits and procedures will be included in the clinical study report for this protocol.  
 
11.1.1.  Safety ECG  
A full standard 12 -lead ECG will be performed (after the subject  has rested in supi[INVESTIGATOR_282112] 10-15 minutes) and centrally read  at as specified in Table  3. 
   
11.1.2.  Laboratory Evaluations  
The Schedule of Eva luations  (Table  3) shows the days at which blood will be collected for 
clinical laboratory tests and urine for the urinalysis .   
 
The table below, Table 5, presents the clinical laboratory tests to be performed.    
 
Clinical la boratory tests will be performed by a certified laboratory that will forward laboratory 
data to both the site and Vanda or its designee.   
 
Values considered to be potentially clinically notable are provided in Appendix  20.3 for the 
Investigator’s guidance. Any laboratory test  result from an enrolled subject  that the Investigator 
consi ders clinically significant may  be repeated once to rule out laboratory error.   For tests where 
a persistent abnormality is considered to be drug related, repeat analyses will be performed until 
the cause is determined and either a return to normality occurs or the Investigator deems the 
abnormality to be of no clinical significance .  Any l aboratory test result that the I nvestigator 
considers clinically significant must also be r ecorded as an adverse event.  
 
Table 5: Clinical Laboratory Tests  
Category  Parameters  
Hematology   Red blood cell count (RBC), hemoglobin, hematocrit, platelets, and 
white blood cell (WBC) count with differential (neutrophils, 
lymphocytes, monocytes, eosinophils, basophils)  
Chemistry   
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276587]  alkaline phosphatase, aspartate aminotransferase (AST [SGOT]), 
alanine aminotransferase (ALT [SGPT]), total bilirubin, gamma -
glutamyltransferase (GGT)  
Renal function parameters  blood urea/blood urea nitrogen (BUN), creatinine , eCLcr  
Other  glucose, calcium, albumin, total cholesterol, high density lipoprotein 
(HDL), low density lipoprotein (LDL), triglycerides, phosphorus, lactate 
dehydrogenase (LDH), total protein, uric acid, creatine kinase  
Urinalysis   
Gross and chemical exam  color, appearance, specific gravity, pH, protein, glucose, ketone, blood, 
nitrite  
Reflexive microscopic exam  
(will be done if any of the 
urinalysis testing is not 
negative)  RBC, WBC, epi[INVESTIGATOR_1663], bacteria, casts, crystals  
 
[IP_ADDRESS].  Additional Laboratory Evaluations  
• Serum pregnancy test at Visit s 1, 4/4a,6, COLE -V1, and COLE -V7 
• Urine pregnancy test at Visits 2 , 3, 5, 6, and COLE V2 -V6. 
• Drugs of abuse at  all visits   
• Thyroid stimulating hormone (TSH) at all visits  
• Thyroxine (T4) at all visits  
• HbA1c  measurement at all visits  
 
11.1.3.  Vital Signs and Body Measurements  
[IP_ADDRESS].  Vital Signs  
Vital signs will be taken as specified in the Schedule of Evaluations  (Table  3). Measurements 
will include the following:  
• Oral b ody temperature  
• Respi[INVESTIGATOR_697]  
• Semi -supi[INVESTIGATOR_42441] (systolic and diastolic)   
• Semi -supi[INVESTIGATOR_909315] / heart rate   
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276588]  signs the informed consent, vital sign values that the Investigator considers 
clinically significant will be recorded as AEs.  Vital sign values considered to be potentially 
clinically notable are provided in Appendix 20.4 for the Investigator’s guidance.  The recording 
must be in the form of a clinical sign, symptom, or diagnosis, and not a mere description of the 
vital sign abnormality.  Measurements will be repeated at medically appropriate intervals until 
they return to acceptable levels.  
 
[IP_ADDRESS].  Body Measurements  
Body measurements include the following assessments:  
• Body weight (at Visit 1 , Visit 2 , and Visit 4) 
• Height  (at Visit 1 only ) 
 
11.1.4.  Medical History and Physical Examinations  
A medic al history will be taken at Visit 1 ( Screening ).  A full PE (excluding pelvic, rectal and 
breast examinations unless clinically indicated)  will be performed at Visit 1 ( Screening ), Visit  
4/a, and Visit 6.  Documentation of the PE will be included in the source documentation at the 
investigational site.   
 
11.1.5.  Pregnancy  
Before enrolling a woman  of child -bearing potential ( WOCBP ) in this clinical study, Investigators 
must review the following information with the subject : 
• Informed consent requirements  
• Risk of pregnancy  
• Contraceptives in current use  
• Drug interactions with hormonal contraceptives  
• Pregnancy prevention during the study  (including abstinence)  
 
All WOCBP (defined as any female unless surgically sterile or postmenopausal at least  12 months) 
should be instructed to contact [CONTACT_909343].   Any pregnancy that occurs during study participation must be 
reported to Vanda  (or designee)  within [ADDRESS_1276589]  becomes pregnant, she  will be discontinued from the study.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
51 
CONFIDENTIAL  11.1.6.  Columbia -Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS is a semi -structured clinical interview designed to systematically assess and track 
suicidal adverse events (behavior and ideation) throughout different settings including clinical 
trials.  This scale was developed by [CONTACT_909344] ( Table  3).  The Screening/Baseline 
version of the C -SSRS will be completed at Visit [ADDRESS_1276590] .  
These data will also be summarized for each treatment group and for suicidal ideation events, 
suicidal behaviors and completed suicides.  
 
11.1.7.  Definitions Related to Safety  
[IP_ADDRESS].  Adverse Event  
An adverse event  (AE) is defined as any untoward medical occurrence in a clinical investigation 
subject  that does not necessarily have causal  relationship with treatment.  An AE can therefore 
be any unfavorable and unintended sign (including clinically significant abnormal laboratory 
finding), symptom, or disease temporally associated with clinical study whether or not related to 
the investigat ional product.  
 
Clinically significant findings or changes in assessments should be recorded as AEs. Every 
attempt should be made to describe the AE in the form of a diagnosis.  If a clear diagnosis has 
been made, individual signs and symptoms will not be recorded unless they represent atypi[INVESTIGATOR_909316], in which case the y should be reported as separate 
events.  If a clear diagnosis cannot be established, each sign and symptom mu st be reported 
individually.    
 
[IP_ADDRESS].  Serious Adverse Event  
AEs are classified as serious or non -serious.  A serious adverse event  is defined as any untoward 
medical occurrence that occurs during clinical study that meets one of the following criteria  as 
shown in Table  6. 
 
Table  6: SAE Criteria and Definitions  
SAE Criteria  Definition  
Death of Subject  An event that results in the death of the subject . 
Life-Threatening  An event that, in the opi[INVESTIGATOR_689], would have 
resulted in immediate fatality if medical intervention had not been 
taken.  This does not include an event that would have been fatal if 
it had occurred in a more severe form.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276591] ’s hospi[INVESTIGATOR_4408].  
Congenital Anomaly/Birth Defect  An anomaly detected at or after birth, or any anomaly that results 
in fetal loss.  
Persistent or Significant 
Disability/Incapacity  An event that results in a condition that substantially interferes with 
the activities of daily living of a study subject .  Disability is not 
intended to include transient interruptions of daily activities or 
experiences of relatively minor medical significance such as 
headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma (e.g., sprained ankle).                                                                                                            
Important Medical Event Requiring 
Medical or Surgical Intervention to 
Prevent Serious Outcome1 An important medical event that, based on medical judgment, may 
not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_059], but may jeopardize the subject  and may require 
medical or surgical intervention to prevent any of the outcomes 
listed above (i.e., death of a subject , life -threatening, subject  
hospi[INVESTIGATOR_059], prolongation of existing hospi[INVESTIGATOR_059], congenital 
anomaly, or persistent or significant disability/incapacity).  
1 Important Medical Events may be classified as serious or non -serious events at the discretion of the Investigator.  
 
All AEs that do not meet the above criteria should be classified as non-serious adverse events.   
Elective surgeries requiring hospi[INVESTIGATOR_909317].  
 
[IP_ADDRESS].  Adverse Event Follow -Up 
Subject s with non -serious AEs that are ongoing at the subject ’s last study visit must be followed 
until resolution or for [ADDRESS_1276592] ’s last study visit, whichever comes first.  Non -
serious AE that are reported during the [ADDRESS_1276593] ’s last study visit will be 
recorded on the Adverse Events CRF and followed until resolution or for up to the [ADDRESS_1276594] ’s last study visit, whichever comes first.  S AEs will be followed until the event resolves 
or the event or seque lae stabilize.  S AEs that are reported within [ADDRESS_1276595] ’s last study 
visit should be reported as indicated in Section 11.1.10 . 
 
[IP_ADDRESS].  Adverse Event Reporting Period  
AEs are to be recorded in the source documents from the time of the subject ’s informed consent 
signature [CONTACT_909372] ’s study participation.  Each AE, both serious and non -serious, 
will also be reported on the Adverse Events CRF.  CRF Completion Instructions will be provided 
to each investigational site.  If the subject  reports or the Investigator learns of a new AE(s) up to [ADDRESS_1276596] ’s last study visit or a new SAE(s) up to [ADDRESS_1276597] ’s last study 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276598] be reported may be extended if 
there is a strong suspi[INVESTIGATOR_909318] m edication or a study 
procedure.  
 
[IP_ADDRESS].  Pre-Existing Condition  
A pre -existing condition is one that is present at the start of the study.  A pre -existing condition 
should be recorded as an adverse event if the frequency, intensity, or the characteristics of the 
condition worsen during the study period.  
 
11.1.8.  Relationship to Study Medication  
Each AE is to be reported on the AE CRF.  The Investigator is responsible for making an 
assessment of the likelihood that an AE is causally related to the study medication.  The 
Investigator should choose one of the five choices of causality.  
• Certain : occurs in a reasonable time after study drug administration and cannot be 
explained by [CONTACT_909345].  The event should respond to withdrawal of 
study drug (de -challenge) and recur with re -challenge when clinically plausible.  
• Probable:  occurs in a reasonable time after study drug administration and it is unlikely 
to be to be attributed to concurrent disease or drugs, and it has a response to de -
challenge.  Re -challenge information is not required to fulfill this definition.  
• Possible:  occurs in a reasonable time after study drug administration, but could be 
related to concurrent disease or drugs. De -challenge information may be lacking or 
unclear.  
• Unrelated:  the event has an improbable temporal relationship (too soon, or too late 
after study drug, or study drug is not taken) and is plausibly related to other drugs or 
underlying disease.  
• Unas sessable:   available information is insufficient, contradictory, and cannot be 
supplemented or verified at the time of the report. This assessment will be considered 
as “related” for all expedited reports until an alternative assessment is made.  
Adverse Event causality of “certain”, “probable”, “possible”, and “unassessable” wil l be 
considered related to study medication.  
 
11.1.9.  Recording Adverse Events  
[IP_ADDRESS].  Adverse Events During Study Period  
At each study visit, the Investigator must seek information on AEs by [CONTACT_909346], as appropriate, by [CONTACT_909347] .  Information on all AEs should be recorded 
immediately in the source document, and also in the appropriate AE module of the CRF.  All 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276599] be recorded.  
 
[IP_ADDRESS].  Post-Study Adverse Event  
At the last scheduled visit, the Investigator should instruct each subject  to report any subsequent 
event(s) that the subject  or the subject ’s personal physician believes might reasonably be related 
to participation in this study.  The Investigator should notify the study sponsor of any death or 
AE occurring at any time after a subject  has discontinued or terminated study participation that 
may reasonably be related to this study.  The Investigator should also notify the sponsor if they 
become aware of the development of cancer or a congenital anomaly in any offspring conceived 
subsequent to a subject ’s study participation.  
 
[IP_ADDRESS].  Abnormal Laboratory Values  
Abnormal laboratory values or test results should not generally be considered adverse events, 
unless deemed clinically significant by [CONTACT_737].  Assessment of signs or symptoms or 
requirement for therapeutic intervention should be considered when d etermining clinical 
significance.  Record clinical significant laboratory values on the Adverse Events CRF using an 
appropriate diagnostic description.    
 
11.1.10.  Reporting Adverse Events  
[IP_ADDRESS].  Study Sponsor Notification by [CONTACT_909348] 24 hours to the Vanda Drug Safety 
designee using the AE electronic CRF page.  
 
The initial report should contain as much information about the event as possible.  Follow -up 
reports will provide any information missing at the time of the initial report (e.g., an end date for 
the adverse event or laboratory values received after the re port).  In addition, significant new 
information on ongoing SAEs  should be reported promptly to Vanda (or designee) . 
  
The initial and follow -up reports should identify subject s by a unique subject  ID rather than by 
[CONTACT_1130] s’ names, personal identification numbers, and/or address.   
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
55 
CONFIDENTIAL  At the time of the initial report, the information listed in Table 7 should be provided.  
 
Table 7: SAE Reporting Information  
• Event term  
• Event d ate of onset  
• Brief narrative with relevant 
medical history  • Action taken regarding study medication 
administration  
• Seriousness criteria met  
• Initial PI [INVESTIGATOR_909319]  
 
 
[IP_ADDRESS].  Repor ting of Events to Regulatory  Authorit ies and IRB/EC  
Investigator or designee  will submit events to the IRB/EC according to individual committee 
requirements. Vanda or designee will submit e xpedited reports of relevant events to Regulatory 
Authorities  as required by [CONTACT_909349].  Events will be reviewed for medical 
sense, expectedness, and causality.  
 
11.1.11.  Unblinding Procedures  
The subjects and the medical staff will not be aware of which treatment is being administered.  
Data will remain blinded until clinical data have been reviewed, at which time the randomization 
schedule may be released for the purposes of assessment of drug  safety and efficacy.  
 
Only if a subject’s medical condition warrants, such as a medical emergency for which treatment 
requires knowledge of what study medication was given, may the Investigator break the blind to 
determine  if the subject received tradipi[INVESTIGATOR_909320].  If possible, the Medical Monitor shou ld 
be consulted prior to unblin dng. If a subject’s condition is so severe that time would not permit 
consulting with the Medical Monitor , the subject’s assigned treatment can be unblinded by [CONTACT_909350].   In the event that it becomes necessary to unblind a 
subject’s treatment assignment during the study, the Investigator should co ntact the Medical 
Monitor  immedi ately, if not prior to unblinding, and explain the reason for unbli nding.   
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276600] response to treatment with tradipi[INVESTIGATOR_909321]/or relative 
susceptibility to side effects.  In addition, the sample may be used to identify genetic markers 
that may be associated with gastroparesis,  disorders  associated with NK -1 rece ptors, or in the 
metabolism, distribution, and/or excretion of tradipi[INVESTIGATOR_181931] .   Information 
regarding this collection and assessment will be provided in the informed consent form.  
 
All subjects enrolled in VP -VLY -686-[ADDRESS_1276601] a pharmacogenomics sample collected. A 
blood sample will be drawn at Baseline (or any other visit if the blood draw is missed) to obtain 
sufficient DNA for the pharmacogenomic assessment.  The blood is drawn into a n EDTA tube  
which will be gently inverted several times to prevent clotting. The sam ple(s) will then be placed 
in a -70 °C or -20 °C freezer at the site.  The sample(s) will be shipped on dry ice to a central 
laboratory for DNA extraction.  The sample will remain under control of the Sponsor and may be 
stored for up to 15 years.   
 
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276602] with the 5% signicance level, the planned sample size of 75 subjects  
per arm (a total of 150  subjects) provides around 8 6% power to detect a mean difference of 0.[ADDRESS_1276603] deviation  of 1.6 in each 
treatment group .     
 
13.2. Statistical Methods  and Analysis Plan  
This section describes the planned statistical analyses in general terms.  A complete description 
of the methodology will be specified in a statistical analysis plan (SAP). Any changes in the 
statistical methods described in this protocol that occur prior to database lock will be 
documented in the SAP and will not require a protocol amendment.  
 
13.2.1.  General  
Statistical analyses will be performed using two -sided tests.    
 
Data will be summarized by [CONTACT_1570] (and by [CONTACT_909351]), with respect to 
demographic and baseline characteristics, efficacy variables, and safety variables.  
 
Summary statistics will include the mean, N, standard deviation, median, minimum, and 
maximum values for continuous variables, and frequencies and percentages for categorical 
variables.  
 
Continuous efficacy variables will be analyzed using a mixed -effect model for repeated measures 
(MMRM) and/or an analysis of covariance  (ANCOVA)  model. The model s will be described in 
the SAP. 
 
For the analyses of change from baseline, only subjects with a baseline and at least one (1) post -
baseline measure will be included in the analysis. Unless otherwise specified, baseline is defined 
as the latest non -missing observation across all the visits in the screening phas e, before the active 
study drug begins. Endpoint will be the latest non -missing observation across all the post -
baseline visits  in the evaluation  phase . 
 
Low enrolling sites will be pooled for analysis and the pooling algorithm will be determined 
prior to breaking the blind .  The goal of pooling low enrolling sites is to have a sufficient number 
of subjects per treatment group within a site for the analysis models and for the evaluation of the 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
58 
CONFIDENTIAL  treatment -by-site interaction for the primary endpoint.  Unless otherwise specified, the pooled 
sites will only be used in the analyses where site is included .  The actual sites rather than the 
pooled sites will be specified in data listings.  
 
Categorical variables will be analyzed using the Cochran -Mantel -Haenszel (CMH) test blocking 
on sites, and Fisher’s exact test will be used when site is not adjusted (mainly for safety 
assessment) . 
 
Details of the model and the analyses will be specified in the SAP.  All statistical analyses will 
be performed using SAS®, Version 9.1.[ADDRESS_1276604] Populations for Analysis  
The following analysis populations will be defined for this study:  
Intent -to-Treat : will include any subject randomized into the study that receives a dose of 
study drug and that has completed at least one post -baseline efficacy measurement while on 
study medication ;   
Safety : Any subject randomized into the study that receives a dose of study drug ; 
Per-Protocol : Any subject who is randomized and receives the protocol required study drug 
exposure and required protocol processing.   
 
Efficacy  analyses will be performed on the Intent -to-Treat population  and the Per -Protocol 
population .  Safety summaries will be based on Safety set.  Subject characteristics will be 
presented for all subjects randomized.  
 
13.2.3.  Subject Disposition  
Study completion and reasons for discontinu ation for all randomized subject s in the double -blind 
phase will be summarized for each trea tment group .    Discontinuations by [CONTACT_909352].  
 
Time to discontinuation due to  adverse events, lack of efficacy  and for any reason will be 
analyzed using Kaplan -Meier survival techniques; the log -rank test will be used for group 
comparison.  
13.2.4.  Demography and Other Baseline Data  
Demographic data and subject characteristics at screening/baseline will be listed and summarized 
by [CONTACT_909353].  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276605] and current medical history will be summarized by [CONTACT_909354] (SOC) as coded using the Medical Dictionary for Regulatory Activities (Me dDRA) coding 
dictionary.  
 
Past medical conditions  will be defined as an onset date prior to randomization ( Visit 2 ) and 
resolved (not on -going) as of Visit 2 .  Current medical conditions, defined as an onset date on or 
after the date of randomization ( Visit 2 ) or an onset date prior to randomization ( Visit 2) and 
unresolved (on -going) as of Visit [ADDRESS_1276606] and a current (on -going) medical condition record are indicated for a 
condition, the condition will be presented under current medical conditions only.  
 
13.2.5.  Study Medication  
The number of subjects at each visit will be summarized by [CONTACT_1570].  
 
The compliance to study medication, as recorded in the CRF , will also be summarized by 
[CONTACT_1570].  The proportion of subjects who are significantly noncompliant in the double -
blind  phase will be summarized by [CONTACT_6660].  
 
13.2.6.  Prior/Concomitant Therapy  
Any medications or therapy present before the first dose of study medication ( Visit 2 ) will be 
considered as prior medications.  Concomitant medications (medications present while on study 
medication) will be recorded throughout the study and at early discontinuation .  These 
medications will be coded using the WHO -drug dictionary.  The number of subjects from the 
Safety Population  using prior or concomitant medications will be categorized by [CONTACT_14300] -drug 
category and preferred term, and presented for each treatment group.  In any given category (e.g., 
drug category) a subject will be counted only once.  
 
13.3. Efficacy Data Analysis  
13.3.1.  Primary Outcome  and Methodology  
The primary efficacy outcome measure will be change from baseline to Day 28 in the weekly 
average of daily nausea severity score .  A repeated measures analysis employing a restricted 
maximum likelihood (REML) -based, mixed -effects model approach (MMRM) will be used to 
analyze the primary efficacy outcome.   The MMRM model will include the fixed, categorical 
effects of treatment group assignment, visit, treatment group -by-visit interaction and pooled site 
as well as the fixed, continuous covariates of baseline  symptom  score and the baseline symptom  
score -by-visit interaction.  A detailed description of the MMRM model will be included in the 
SAP.   
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
60 
CONFIDENTIAL  In addition to the MMRM   model , an analysis of covariance (ANCOVA) model will also be 
applied. The last -observation -carried -forward (LOCF) will be used to impute any subsequent 
missing data. The model will have baseline as a covariate, and the fixed, categorical effects of 
treatment group assignment, pooled site.  An observed cases (OC) analysis will also be 
performed.  
 
As stated previously, any changes in the statistical methods that occur prior to database lock will 
be documented in the SAP and will not require a protocol amendment.  
  
13.3.2.  Secondary Efficacy Analysis  
The secondary efficacy outcomes include:  
• Other Gastroparesis Core Sym ptoms: vomiting, early satiety, post -prandial fullness, 
and upper abdominal pain;  
• mGCSI  
• mPAGI -SYM  
• PGI-C 
• PAGI -QOL  
• GTBS  
• CGI-S 
 
Continuous endpoints  will be summarized and analyzed in a manner similar to the primary 
endpoint . Details of the analysis  will be described in the SAP.  
 
Categorical variables will be evaluated as described in the SAP.  Time to event data will be 
analyzed using the Kaplan -Meier method, and the treatment group differences will be tested by 
[CONTACT_63450] -rank test. Details of the analysis will be  described in the SAP.  
 
13.4. Safety Data  Analysis  
The primary assessment of safety will be based on the frequency of treatment -emergent adverse 
events  (TEAEs) , serious adverse events (SAEs) and on the frequency of clinically notable 
abnormal vital signs , electrocardiograms (ECGs) and laboratory values. Other safety evaluations 
include changes in vital signs, changes in clinical laboratory evaluations, and changes in ECGs, 
physical exam findings during treatment, and suicide ideation and behavior events.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
61 
CONFIDENTIAL  13.4.1.  Adverse Events  
Adverse events will be recorded throughout the study and at early discontinuation . Adverse 
events and medical conditions will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) coding dictionary.  Treatment -emergent adverse events will be defined as 
those events, which are newly occurring or worsening from baseline.  In all cases only treatment 
emergent adverse events will be summarized.  
 
Treatment -emergent adverse events will be summarized within each treatment group by [CONTACT_230782] (SOC) and preferred term. (NOTE : In any given category [e.g. body system] 
a subject will only be counted once.) The incidence rates of TEAEs will be analyzed as described 
in the SAP.  Similar displays will be provided for SAE and prior (conditions ending prior to the 
first dose of study medication  and current (conditions present while on study medication) 
medical conditions.  
 
Adverse events will further be categorized by [CONTACT_926], relationship to study medication, and 
action taken. Other information collected will be listed, as appropriate. Any event starting more 
than 3 days after the final dose of study medication will be exc luded from the above tables and 
only listed, unless the event caused discontinuation.  
 
The proportions of subjects  experiencing SAEs and AEs resulting in discontinuation from the  
study will be summarized by [CONTACT_6660].   
 
13.4.2.  Laboratory Data  
Clinical Laboratory Data  
The summary statistics of raw data (hematology and chemistry) and change from baseline values 
will be presented, as well as shift tables from baseline to post -baseline values using normal 
ranges.  For urinalysis parameters, the number and percentage of sub jects falling under each 
category of the test will be presented.  
 
Clinical laboratory data will be summarized for each treatment group by [CONTACT_909355] ( Appendix  20). 
 
Clinically notable values will be identified according to the criteria identified in the FDA's 
"Supplementary Suggestions for Preparing an Integrated Summary of Safety Information in an 
Original NDA Submission and for Organizing Information in Periodic Saf ety Updates" (Revised 
2-APR -87) provided by [CONTACT_88595] (DNDP).   
Differences in incidence rates between the treatment groups will be tested as described in the 
SAP.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
62 
CONFIDENTIAL  13.4.3.  Vital Signs and Body Measurements  
Data from vital signs and body measurements will be listed, clinically notable values ( Appendix 
20.2) will be flagged, and any other information collected will be listed. Data will also be 
summarized by [CONTACT_909356], and values that were clinically notable.  
 
13.4.4.  Electrocardiogram (ECG)  
Results from the ECG will be listed for each subject. These data will also be summarized for 
each treatment group by [CONTACT_909357].  
 
13.4.5.  C-SSRS  
Results from the C -SSRS will be listed for each subject.  These data will also be summarized by 
[CONTACT_909358], suicidal behaviors and completed suicides. In 
particular, for each of the following suicide related events, the number and percent of subjects  
with the event will be enumerated by [CONTACT_2948] : completed suicide, nonfatal suicide 
attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, active suicidal 
ideation with specific plan and intent, active suicidal ideation with some intent to act without 
specific plan, active suicidal ideation with any methods (no plan) without intent to act, non -
specific active suicidal thoughts, and wish to be dead.   Details of the analysis will be provided in 
the SAP.  
 
13.5. Subgroup Analysis  
The subgroup analysis (such as, gender, age, etiology, baseline illness severity etc.) for efficacy 
variables and safety variables may be conducted as described in the SAP . 
 
13.6. Interim Analysis  
No interim analyses are planned.  
 
13.7. Deviations in Analysis from Statistical Plan and Other Issues  
During the analysis and reporting process, any deviations from the statistical plan designed for 
this protocol will be described and justified in the final report.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276607] ACCESS TO SOURCE DOCUMENTS  
14.1. Definition of Source Document  
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source documents.  Examples of these or iginal documents and data records 
(ICH E6, Section 6.10) include, but are not limited to: hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, subject s’ diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from  automated instruments, copi[INVESTIGATOR_14848], microfiches, photographic negatives, microfilm or 
magnetic media, X -rays, subject  files, and records kept at the pharmacy, at  the laboratories, and 
at medical or technical departments involved in the clinical trial.  The Investigator is required to 
maintain adequate and accurate source documents that record all observations and other data 
pertinent to this study.  
 
14.2. Study Monitoring  
The Sponsor’s or CRO’s monitor will maintain contact [CONTACT_909359].  Monitoring visits to each investigational site will be conducted by [CONTACT_909360].  The Investigator must 
designate an adequate space to conduct the monitoring visit and will allocate adequate time for 
Vanda’s monitoring activities.  The CRFs and subject ’s corresponding original medical records 
(source documents) are to be fully avai lable for review by [CONTACT_2037].   
 
The purposes of clinical trial monitoring are to verify that:  
• the rights and well -being of the human subject s are protected;  
• reported trial data are accurate, complete and verifiable from source documents;  and 
• trial conduct is in compliance with the currently approved protocol/amendment(s), 
with GCP, and with applicable regulatory requirement(s).  
 
14.3. Audits and Inspections  
In addition to routine monitoring procedures, Vanda may request an independent Good Clinical 
Practice Quality Assurance contractor to perform audits of clinical research activities to evaluate 
compliance with principles of Good Clinical Practice.  The Inve stigator will ensure that the 
compliance or quality assurance reviewer is allowed to:  
• review all of the study -related documents (e.g., study records and source documents) 
and study related facilities (e.g., pharmacy, diagnostic laboratory)  
• discuss the conduct of the study with the Investigator  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276608] an inspection (during the study or even after its 
completion).  If an inspection is requested by a regulatory authority, the Investigator must inform 
the CRO and Vanda immediately that this request has been m ade, and promptly forward copi[INVESTIGATOR_909322].  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276609] 
Operating Procedures (SOPs), working practice documents, and applicable regulations and 
guidelines.  Site visit audits will be made periodically by [CONTACT_1034]’s (or CRO’s) qualified 
compliance auditing team, which is  an independent function from the study conduct team.  
 
15.1. Data Collection  
The study CRF is the primary data collection instrument for the study.  All data requested on the 
CRF must be recorded.  All missing data must be explained.  A detailed guideline on the 
completion of the CRF will be provided to the site.   Monitors will highlight any discrepancies 
found in the documentation of study conduct and ensure that appropriate site personnel address 
the discrepancies.   
 
15.2. Clinical Data Management  
 Data from the CRFs and other external data (e.g. laboratory data) will be entered into a clinical 
database as specified in the Sponsor (or CRO’s) data management plan.  Quality control and data 
validation procedures will be applied to ensure the validity and accuracy of the clinical database.  
 
15.3. Database Quality Assurance  
The clinical database will be reviewed and checked for omissions, apparent errors, and values 
requiring further clarification using computerized and manual procedures.  Data queries 
requiring clarification will be documented and returned to the investigati onal site for resolution.  
Only authorized personnel will make corrections to the clinical database, and all corrections will 
be documented in an audit trail.    
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
66 
CONFIDENTIAL  16. ETHICS  
16.1. Ethics Review  
This protocol and any amendments will be submitted to a properly constituted EC or IRB, in 
agreement with local legal prescriptions (ICH 3.1 -3.4), for formal approval of the study conduct.   
 
All subject s for this study will be provided a consent form describing this study and providing 
sufficient information for subject s to make an informed decision about their participation in this 
study.  This consent form will be submitted with the protocol for review and approval by [CONTACT_28923]/IRB for the study.  The formal consent of a subject  by [CONTACT_3878], using the 
EC/IRB -approved consent form, must be obtained before that subject  is submitted to any study 
procedure.  This consent form must be s igned by [CONTACT_423] , or subject ’s legally acceptable 
surrogate, and the Investigator -designated research professional obtaining the consent.  
 
16.2. Ethical Conduct of the Study  
This study is to be conducted according to US and international standards of Good Clinical 
Practice, as described in the following documents:  
1. ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996.  
2. US Code of Federal Regulations (CFR) dealing with clinical studies (21 CFR including 
parts 50 and 56) . 
3. Declaration of Helsinki (current)  
The Investigator agrees, when signing the protocol, to adhere to the instructions and procedures 
described in it and thereby [CONTACT_220168].  
 
16.3. Written Informed Consent  
Prior  to any study procedures being performed, subjects and persons conducting the consent 
process will be required to sign and date the IRB/EC approved informed consent, and each 
subject will be given a copy. In addition, this information  should be recorded in the subject’s 
medical record.  The written consent document will embody the elements of informed consent as 
described in the Declaration of Helsinki, US 21 CFR Part 50.25, ICH GCP, and in accordance 
with any local regulations. The In vestigator is res ponsible for the preparation, content, and 
IRB/EC approval of the consent form.  The consent form must be approved by [CONTACT_1201]/EC and 
be acceptable to the study Sponsor or designee. The consent form must be written in language 
fully comprehensible to the prospective subject.  The Investigator or designee  will give the 
subject adequ ate opportunity to read the consent form and to discuss any questions.  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276610] 
identification number.  However, subjects’ initials and date of birth may also be collected in 
accordance with local and/or country regulations, and used to assist the Sponsor or designee with 
verification of data.  This data will be blinded in corresponding analyses. Medical records of 
consented subjects will be re viewed by [CONTACT_909361], but not limited to, 
laboratory test results, ECG reports, hosp ital admission and discharge summaries for admissions 
occurring during a subject’s participation in the study, and autopsy reports for deaths occurring 
during the study. The Sponsor and/or designee accessing the records will take all reasonable 
precautions  in accordance with applicable laws, regulations, and guidelines to maintain the 
confidentiality of subject identities.  
Should access to such medical records require a waiver or authorization separate from the 
statement of informed consent, the Investigator will obtain such permission in writing from the 
subject before the subject is entered into the study.  
 
Samples collected for pharmacogenomic study will be double -coded by [CONTACT_38733]: 
(1) The sample is collected at the site in a tube labeled with a barcode - code #1.      (2) The 
sample is then sent to a central lab for storage and DNA extraction.   An aliquot of the DNA 
sample is sent to Vanda where it will be identified with a new unique code – code #2.  The 
sample is now double -coded.  This maximizes subject confidentiality.   
 
The DNA sample and any information generated from this sample will be labeled with the 
second code and no personal identifiers.  In addition, all genetic information will be stored in a 
separate secured database, independent from the clinical data database.  Only authorized 
personnel from Vanda will have access to the genetic data.  In addition, the FDA or other 
regulatory agencies may request copi[INVESTIGATOR_909323].  Unl ess ordered 
by a court of law, only the above mentioned agenc ies and personnel will have access to the 
genetic data.  
 
17.1. Retention of Records  
It is the Investigator’s responsibility to retain essential study documents for at least [ADDRESS_1276611] approval of a marketing application in his/her country for the investigational product and 
until there are no pending or contemplated marketing applications in his/her country, or at least [ADDRESS_1276612] written approval from the sponsor to dispose of the study documents.  
These documents sh ould be retained for a longer period if required by [CONTACT_909362] .  In such an instance, it is the responsibility of the sponsor to 
inform the Investigator/institution as to when these documents no longer need to be retained. The 
Investigator must receive Sponsor approval prior to destroying any records associated with the 
study.   
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276613] be 
approved by [CONTACT_909363]/EC and regulatory agency submission. The Investigators must 
sign the amendment before implementation.   
 
Substantial amendments require approval from the regulatory a uthority and/or the responsible 
ethics committee. Amendments to the trial are regarded as “substantial” where they are likely to 
have a significant impact on:  
• the safety or physical or mental integrity of the subjects, or  
• the scientific value of the trial, or  
• the conduct or management of the trial, or  
• the quality or safety of any IMP used in the trial.  
 
In addition, if amendments affect the informed consent, a revised informed consent has to be 
submitted to the responsible ethics committee, before changes in study procedures are 
implemented.  These requirements for approval should in no way prevent any im mediate action 
from being taken by [CONTACT_909364]. If an immediate change to the protocol is felt to be necessary by [CONTACT_49248]/he r for safety reasons, the Vanda monitor and the IRB/EC 
at the center should be notified.  
 
Amendments affecting only administrative aspects of the study do not require formal protocol 
amendments or Ethical Committee  approval but the Ethical Committee  must be kept informed of 
such administrative changes.   
 
18.2. Discontinuation of Study   
Vanda reserves the right to discontinue any study for administrative reasons at any time. If 
appropriate, reimbursement for reasonable expenses will be made.  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
69 
CONFIDENTIAL  18.3. Publication of Results  
Manuscript(s) for publication, texts of presentations, abstracts of papers, and similar material 
should be submitted to Vanda for review and comment at least sixty (60) days prior to submission 
for publication, public dissemination or review by a program c ommittee.  Upon request from 
Vanda, the site shall remove any confidential information (other than study results) prior to 
submitting or presenting the materials.  Vanda shall notify the Investigator in writing within sixty 
(60) days of receipt of such dra ft whether it contains information deemed to be confidential or 
information that if published within thirty (30) days would have an adverse effect on Sponsor’s 
business interests, including but not limited to a patent application in which Vanda owns an 
interest.  In the latter case, Vanda may request a delay and Investigator agrees to delay publication 
or presentation for a period not exceeding ninety (90) days.  An independent joint publication may 
be authored by [CONTACT_909365].  The  Investigator, therefore, agrees not to 
independently publish the results of the study before the publication of such multi -site paper, if 
applicable.  No party heretofore mentioned shall use any other party’s name, or Vanda’s name, in 
connection with any advertising, publication, or promotion without prior written permission.  
  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
70 
CONFIDENTIAL  18.4. Investigator Agreement  
This protocol is being provided to me for conducting a clinical trial for Vanda.  The information 
contained in the protocol is confidential and proprietary to Vanda.  Study documents provided by 
[CONTACT_909366] (protocols, Investigator’s Brochures, and other materia l) will be stored appropriately to 
ensure their confidentiality.  
I may disclose the contents of this protocol to study personnel under my supervision and my 
Institutional Review Board or Ethical Committee  for the purpose of conducting this trial only.  
The information provided by [CONTACT_909367], except to the extent necessary to obtain informed consent from 
subject s who wish to participate in the trial.  
I have read the protocol and agree that it contains all necessary details for carrying out the study 
as described.  I will conduct this protocol as outlined and according to the moral, ethical, and 
scientific principles governing the Declaration of Helsink i and the principles of GCP and 
applicable local requirements.  
I understand that should the decision be made by [CONTACT_909368], with or without cause, such decision will be communicated to me in 
writing.  Conversely, if I decide to withdraw from execution of th e clinical trial, I will 
immediately communicate such decision in writing to Vanda.  
By [CONTACT_12006], I attest that I have read, and understood, and agree to abide by [CONTACT_909369], instructions, and restrictions contained in this protocol.   
 
Investigator  
Name: ______________________________________  
Signature: ____________________________________  
Date: ________________________________________  
 
Protocol Number: VP -VLY -686-2301  
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
71 
CONFIDENTIAL  19. REFERENCES  
 
[1] W. L. Hasler, “Gastroparesis: symptoms, evaluation, and treatment,” Gastroenterol.Clin 
North Am , vol. 36, no. 0889 –8553 (Print), pp. 619 –47, ix, Sep. 2007.  
[2] H. P. Parkman, M. Camilleri, G. Farrugia, R. W. McCallum, A. E. Bharucha, E. A. 
Mayer, J. F. Tack, R. Spi[INVESTIGATOR_6942], M. Horowitz, A. I. Vinik, J. J. Galligan, P. J. Pasricha, B. 
Kuo, L. A. Szarka, L. Marciani, K. Jones, C. R. Parrish, P. Sandroni, T. Abell, T. Ordog, 
W. Hasler, K. L. Koch, K. Sanders, N. J. Norton, and F. Hamilton, “Gastroparesis and 
functional dyspepsia: Excerpts from the AGA/ANMS meeting,” Neurogastroenterol. 
Motil. , vol. 22, no. 2, pp. 113 –133, 2010.  
[3] A. E. Bharucha, “Epi[INVESTIGATOR_909324],” Gastroenterol.Clin 
North Am , vol. 44, no. 1558 –1942 (Electronic), pp. 9 –19, Mar. 2015.  
[4] M. Camiller, H. P. Parkman, M. A. Shafi, T. L. Abell, and L. Gerson, “Clinical 
Guideline : Management of Gastroparesis,” Am J Gastroenterol , vol. 108, no. 1, pp. 18 –
38, 2013.  
[5] L. A. Nguyen and W. J. Snape, “Clinical presentation and pathophysiology of 
gastroparesis,” Gastroenterology Clinics of North America , vol. 44, no. 1. pp. 21 –30, 
2015.  
[6] W. L. Hasler, “Emerging drugs for the treatment of gastroparesis,” 
Expert.Opin.Emerg.Drugs , vol. 19, no. 1744 –7623 (Electronic), pp. 261 –279, Jun. 2014.  
[7] H. P. Parkman, K. Yates, W. L. Hasler, L. Nguyen, P. J. Pasricha, W. J. Snape, G. 
Farrugia, K. L. Koch, J. Calles, T. L. Abell, R. W. McCallum, L. Lee, A. Unalp –Arida, J. 
Tonascia, and F. Hamilton, “Similarities and Differences Between Diabetic and Idi opathic 
Gastroparesis,” Clin. Gastroenterol. Hepatol. , vol. 9, no. 12, pp. 1056 –1064, 2011.  
[8] P. J. Pasricha, K. P. Yates, L. Nguyen, J. Clarke, T. L. Abell, G. Farrugia, W. L. Hasler, 
K. L. Koch, W. J. Snape, R. W. McCallum, I. Sarosiek, J. Tonascia, L. A. Miriel, L. Lee, 
F. Hamilton, and H. P. Parkman, “Outcomes and Factors Associated with Re duced 
Symptoms in Patients with Gastroparesis,” Gastroenterology , vol. 149, no. 7, pp. 1762 –
1774e4, 2015.  
[9] M. Otsuka and K. Yoshioka, “Neurotransmitter functions of mammalian tachykinins,” 
Physiol Rev. , vol. 73, no. 0031 –9333 (Print), pp. 229 –308, Apr. 1993.  
[10] L. Quartara and C. A. Maggi, “The tachykinin NK1 receptor. Part II: Distribution and 
pathophysiological roles,” Neuropeptides , vol. 32, no. 0143 –4179 (Print), pp. 1 –49, Feb. 
1998.  
[11] S. M. Stahl, “The ups and downs of novel antiemetic drugs, part 2: An illustration,” J. 
Clin. Psychiatry , vol. 64, no. 6, pp. 626 –627, 2003.  
[12] M. Bergstrom, R. J. Hargreaves, H. D. Burns, M. R. Goldberg, D. Sciberras, S. A. Reines, 
K. J. Petty, M. Ogren, G. Antoni, B. Langstrom, O. Eskola, M. Scheinin, O. Solin, A. K. 
Majumdar, M. L. Constanzer, W. P. Battisti, T. E. Bradstreet, C. Gargano, and J. Hietala, 
“Human positron emission tomography studies of brain neurokinin 1 receptor occupancy 
by [CONTACT_173369][INVESTIGATOR_053],” Biol.Psychiatry , vol. 55, no. 0006 –3223 (Print), pp. 1007 –1012, May 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
72 
CONFIDENTIAL  2004.  
[13] K. Chong and K. Dhatariya, “A case of severe, refractory diabetic gastroparesis managed 
by [CONTACT_909370][INVESTIGATOR_053].,” Nat. Rev. Endocrinol. , vol. 5, no. 5, pp. 285 –8, 2009.  
[14] J. Fahler, G. C. Wall, and B. I. Leman, “Gastroparesis -associated refractory nausea treated 
with aprepi[INVESTIGATOR_053],” Annals of Pharmacotherapy , vol. 46, no. 12. 2012.  
[15] M. Minami, “[Cytokines and chemokines: mediators for intercellular communication in 
the brain].,” Yakugaku Zasshi , vol. 121, no. 12, pp. 875 –85, 2001.  
[16] A. M. Rentz, P. Kahrilas, V. Stanghellini, J. Tack, N. J. Talley, C. de la Loge, E. Trudeau, 
D. Dubois, and D. A. Revicki, “Development and psychometric evaluation of the patient 
assessment of upper gastrointestinal symptom severity index (PAGI -SYM) i n patients 
with upper gastrointestinal disorders,” Qual Life Res , vol. 13, no. 10, pp. 1737 –1749, 
2004.  
 
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
73 
CONFIDENTIAL  20. APPENDICES  
 
20.1. Open -Label Extension Phase  
20.1.1.  Phase Objective  
The objective of the open -label extension ( OLE ) phase is to explore the long -term safety of daily 
dosing with tradipi[INVESTIGATOR_909325] [ADDRESS_1276614] them the opportunity to explore the potential benefits of a new drug treatment not otherwise 
available to them.    
 
20.1.3.  Study Design for OLE Phase  
The OLE phase consists of an additional 8-weeks of treatment where all subjects w ill receive the 
same daily d ose of tradipi[INVESTIGATOR_909326] -label fashion. S ubjects who received tradipi[INVESTIGATOR_909327] r eceive tradipi[INVESTIGATOR_053] . Subjects who received placebo during the 
evaluation  phase will also receive tradipi[INVESTIGATOR_053] .  
 
Subjects will go to the clinic during the OLE on the days specified in the Schedule of Evaluations 
for OLE ( Table 8) for routine safety assessments which may include a urine  pregnancy test for 
women of child -bearing potential (WOCBP), urine drug screen, vital signs measurements, safety 
labs, physical exam, an ECG and collection of adverse event including suicidality ideation and 
behavior and concomitant medication information. Refer to Table 8 and Section  20.1.10   for details 
of which assessments are done per Study Visit. Study medication will be dispensed at some of 
these visits and compliance will also be assessed.  End -of-study (EOS) assessments and an 
additional gastric emptying breath test will be performed at Visit 6 (Study Day 84 ± 3 days ) or at 
the time of early discontinuation. EOS assessments include safety evaluations such as serum 
pregnancy test for females, physical examination (PE), vital signs, ECG,  collection of adverse 
event including suicidality ideation and behavior and clinical laboratory assessments ( Table 8).  
 
 
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
74 
CONFIDENTIAL  Table 8: Schedule of Evaluation s for OLE  
Visit  V4a1 V5 
 V6 
EOP  
Study Day   Day 562 Day 842  
Informed Consent  X   
Prior/concomitant medications  X X X 
Adverse Event (AE) Query3 X X X 
Collection of menstrual cycle information  X X X 
Serum β -HCG (for WOCBP)  X  X 
Urine pregnancy test (for WOCBP)   X  
TSH , T4 X X X 
Urine Drug Screen  X X X 
HbA1c, hematology, chemistry, and 
urinalysis  X X X 
12-lead resting ECG  X X X 
Vital signs and body measurements4 X X X 
Physical Examination (PE)  X  X 
Gastric Emptying Breath Test (GEBT)    X 
C-SSRS5 X X X 
Clinical Global Impression of Severity 
(CGI -S) X 
X X 
PGI-C  X X 
mGCSI & mPAGI -SYM  X X X 
PAGI -QOL  X  X 
Gastroparesis Core Symptom Daily Diary 
(GCSDD)    
Subject diary review   X X 
Study medication dispensation  X X  
VP-VLY-686-2301                                                                               Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9  26 November  2018        
75 
CONFIDENTIAL  Visit  V4a1 V5 
 V6 
EOP  
Study Day   Day 562 Day 842  
Study medication collection & compliance   
X X 
EOP    X 
1 Only for subjects that completed the Double -Blind Phase prior to the OLE being available.  
2 within +/ - 3 days  
3 Adverse event collection will begin at the time the ICF is signed.  
4 Vital sign collection at all visits. Height collection at V1 only.  
5 The Screening/Baseline C -SSRS will occur at V1.  The Since Last Visit C -SSRS will occur at all other visits.  
EOS = End of Study; ET = Early Termination; WOCBP = Women of Child -bearing Potential; ECG = 
electrocardiogram; C -SSRS = Columbia Suicide Severity Rating Scale  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
76 
CONFIDENTIAL  20.1.4.  Selection and Withdrawal Criteria of Subjects for the OLE Phase  
[IP_ADDRESS].  Inclusion Criteria  
A subject is eligible for enrollment into the OLE phase of this study if he/she meets the following 
criteria:  
• Has completed  the randomization phase through Visit 4 (Study Day 28);  
• Is willing to provide an additional written informed consent for the OLE phase  if 
enrolled in study prior to OLE becoming available . 
[IP_ADDRESS].  Early Withdrawal of Subjects  
The term “discontinuation” refers to the randomized subject’s premature withdrawal from the 
study before completing all scheduled evaluations.  
 
Subjects may voluntarily withdraw from the OLE at any time for any reason. Subjects may also 
be discontinued from the study for any of the following reasons:  
• If in the Investigator’s judgment, continuation in the study may prove harmful to the 
subject.  Such a decision may be precipi[INVESTIGATOR_152208], including changes in 
vital signs, physical examination, ECG, or laboratory tests.  The Investigator will 
maintain autonomy in making medical/safety decisions regarding the subject’s 
continued participation in the trial.  Clinically notable abnormalities in vital signs or 
laboratory tests are provided in Appendices  20.[ADDRESS_1276615]’s continued participation;  
• Noncompliance;  
 
Documented reason:    
It will be documented whether or not  each subject completed the clinical study.  If, for any subject, 
study treatment or observations were discontinued, the reason will be recorded (only 1 choice is 
acceptable) on the electronic case report form (electronic CRF).  Acceptable reasons for a su bject 
discontinuing participation in this clinical study are as follows:  
1. Protocol deviation (including noncompliance to study requirements)  
2. Adverse event(s) (including abnormal laboratory values, and abnormal test procedures)  
3. Pregnancy  
4. Lost to follow -up 
5. Death  
6. Subject withdrew consent  
7. Unsatisfactory therapeutic effect  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
77 8. Other (specify).  
20.1.5.  Study Medication  
[IP_ADDRESS].  Dosing  
Subjects will be dispensed study medication under open -label  conditions at the study visits 
indicated in the Schedule of Evaluations  for OLE  (Table 8).  Subjects will be instructed to take 
one capsule of study medication every day in the morning, and one capsule of study medication 
every day in the evening approximately 12 hours later. Each capsule will contain either 85 mg of 
tradipi[INVESTIGATOR_053] . 
 
[IP_ADDRESS].  Guidance for Taking Study Medication  
Subjects should be instructed to take study medication approximately every [ADDRESS_1276616] 
capsule can be identified in the emesis, a second capsule should be administered.  
 
20.1.6.   Concomitant Medication During the OLE Phase  
The administration of concomitant medication (including OTC medication) will be clearly 
documented on the concomitant medication CRF page.  
In general, concomitant medications that may interfere with the assessment of the efficacy and 
safety of tradipi[INVESTIGATOR_909328].  
 
[IP_ADDRESS].  Prohibited Medication  
Prohibited medications and treatments are prohibited from the screening visit (or 4 weeks prior to 
the Randomization Visit when a washout is required) through the end of study participation. 
Questions regarding the use of concomitant medications not listed  should be directed to the 
Medical Monitor.  
All medications prohibited during the randomization phases ( Section  7.2.1 ) will also be prohibited 
during this phase.  
 
[IP_ADDRESS].  Rescue Medication  
Anti-nausea or antiemetic medication that is not administered on a stable daily dosing regimen is 
considered rescue medication. Patients may use rescue medication per the Rescue Medication 
Guidelines  (Section  [IP_ADDRESS] ). 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276617] be recorded on the overdose CRF. An 
overdose (intentional or accidental) is defined as the following: >3 capsules of open label  study 
medication taken within a 24 -hour period (except when re -administered within the guidance of  
Section  7.1.2 ). 
 
20.1.8.  Treatment Assignment  
At study Visits 4/4a, and 5, (Table  3 and Table 8), study personnel will dispense enough OLE 
medication to the subject to last until the next scheduled visit.  
 
20.1.9.  Study Drug, Packaging, and Labeling  
Tradipi[INVESTIGATOR_909329], hard gelatin capsules provided as a strength of 85 mg. The 
85 mg capsule formulation also contains spray -dried lactose monohydrate, microcrystalline 
cellulose (Avicel PH102 and PH200), povidone, croscarmellose sodium,  sodium lauryl sulfate, 
and magnesium stearate as excipi[INVESTIGATOR_840].  
 
Study medication capsules will be provided in high -density polyethylene (HDPE) bottles with a 
child -resistant cap containing desiccant. Each bottle will contain [ADDRESS_1276618]’s source 
documents before the bottle is dispensed to the subject.  
 
Study medication should be stored at 20 -25 °C with excursions permitted to 15 -30 °C. Capsules 
should not be crushed or broken, but should be swallowed whole. Study medication will be 
dispensed to only randomized subjects at the study site.  
 
20.1.10.  Assessments Performed During the OLE  
[IP_ADDRESS].   Visit 4a ( Only for subjects that completed the Double -Blind Phase p rior to the 
OLE being available)  
• Signing of the Informed Consent  
• Review of concomitant medication  
• Adverse event query  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
79 • Serum  pregnancy test and collection of menstrual cycle information (for females of 
child -bearing potential)  
• Clinical laboratory assessments (HbA1C, hematology, chemistry, thyroid stimulating 
hormone (TSH), thyroxine (T4) , urinalysis, and urine drug screen)  
• ECG  
• Semi -supi[INVESTIGATOR_909330] ( weight, body temperature, respi[INVESTIGATOR_697], blood 
pressure, and pulse)  
• Full PE (excluding pelvic, rectal and breast examinations unless clinically indicated)  
• Since last visit C -SSRS  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Clinical Global Impression of Severity (CGI -S) 
• Patient Assessment of Upper Gastrointestinal Diso rder Quality of Life (PAGI -QOL)  
• Study medication dispensation  
 
[IP_ADDRESS].  Visit 5  (Study Day 56  +/- 3 days ) 
• Adverse event query  
• Review of concomitant medication  
• Urine pregnancy test and collection of menstrual cycle information (for females of 
child -bearing potential)  
• Clinical laboratory assessments (HbA1C, hematology, chemistry, thyroid stimulating 
hormone (TSH), thyroxine (T4) , urinalysis, and urine drug screen)  
• ECG  
• Semi -supi[INVESTIGATOR_909330] ( weight, body temperature, respi[INVESTIGATOR_697], blood 
pressure, and pulse)  
• Since last visit C -SSRS  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Clinical Global Impression of Severity (CGI -S) 
• Patient Global Impression of Change (PGI -C) 
• Diary review  
• Study medication collection and review  
• Study medication dispensation  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
80  
[IP_ADDRESS].  Visit 6 (Day 84/EOS ± 3 days or ET)  
• Adverse event query  
• Review of concomitant medication  
• Serum  pregnancy test and collection of menstrual cycle information (for females of 
child -bearing potential)  
• Clinical laboratory assessments (HbA1C, hematology, chemistry  (including e CLcr; 
based on the Cockcroft -Gault equation ), urinalysis, thyroid stimulating hormone 
(TSH), thyroxine (T4), and urine drug screen)  
• ECG  
• Semi -supi[INVESTIGATOR_909330] ( weight, body temperature, respi[INVESTIGATOR_697], blood 
pressure, and pulse)  
• Full PE (excluding pelvic, rectal and breast examinatio ns unless clinically indicated)  
• Gastric Emptying Breath Test (GEBT)  
• Since last visit C -SSRS  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Clinical Global Impression of Severity (CGI -S) 
• Patient Global Impression of Change (PGI -C) 
• Patient Assessment of Upper Gastrointestinal Disorder Quality of Life (PAGI -QOL)  
• Diary review  
• Study medication collection and review  
20.1.11.  Efficacy Assessments  
The efficacy  assessments should be conducted as specified in the Schedule of Evaluation s for 
OLE  (Table 8).  These assessments include:  the Gastroparesis Core Symptom Daily Diary 
(GCSDD) , Modified Gastroparesis Cardinal Sympto m Index (mGCSI), Modified PAGI -SYM 
(mPAGI -SYM), Patient Global Impression of Change (PGI -C), and the Patient Assessment of 
Upper Gastrointestinal Disorders -QOL (PAGI -QOL)  (see Section  10.1.1  for a description of the 
patient reported outcome s) and the Clinician Global Impression – Severity (CGI -S) (see 
Section  10.2 for a description of the assessment).  
20.1.12.  Safety Assessments  
The safety assessments should be conducted as specified in the Schedule of Evaluation s for OLE 
(Table 8).  These assessments include: the regular monitoring and recording of all adverse events 
and serious adverse events (SAEs); the regular monitoring of hematology, blood biochemistry and 
urinalysis values; the regular monitoring of vital signs; the regular monitoring of suicidal ideation 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
81 and behavior , and the performance of physical examinations, and electrocardiograms.  Refer to  
Section  11 for additional details relating to the collection of safety assessments.  
 
20.1.13.  Statistical Methods  
Statistical analysis for the OLE phase will be based on data summaries, using similar layouts as 
for the randomization phase, and will be exploratory in nature.  
 
 
 
  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
82  
20.2. Continued Open Label Extension Phase  
20.2.1.  Phase Objectives  
[IP_ADDRESS].  Primary  
• To evaluate long term dosing of tradipi[INVESTIGATOR_909331] (AEs) including suicidal ideation or behavior, changes in vital 
signs, clinical laboratory evaluations, electrocardiograms (ECGs) and physical exam 
findings during treatment  
 
[IP_ADDRESS].  Secondary  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909332]  
• To evaluate the efficacy of tradipi[INVESTIGATOR_909333]  
 
20.2.2.  Phase Rationale  
[IP_ADDRESS].  Study  Rationale  
The underlying pathophysiology of gastroparesis is complex and remains largely unknown.  
Prokinetic therapy has been the traditional mainstay of gastroparesis treatments, but studies 
continue to demonstrate a lack of correlation between reduction in gastri c emptying delays and 
relief of gastroparesis symptoms [5]. 
 
Two case reports have documented the efficacy of open -label NK -[ADDRESS_1276619] therapy in 
severe, refractory gastroparesis cases [13][14].  Since the treatment of gastroparesis symptoms 
requires chronic administration of tradipi [INVESTIGATOR_053] 85mg, this study evaluates the long -term safety 
and tolerability of 85 mg tradipi[INVESTIGATOR_909334] 12 months.  
 
[IP_ADDRESS].  Rationale for Dose and Study Design  
In a multiple -dose PET clinical study, frontal cortex receptor occupancy was recorded at 93% 
following 7 days of 100 mg daily dosing.  Based on the PET study findings, it is estimated that a 
dose of approximately 85 mg daily would achieve 90% brain recepto r occupancy [ADDRESS_1276620] 
steady -state dosing.  A target brain NK -1 receptor occupancy of 90% is based on a published 
study comparing the efficacy of two different doses in aprepi[INVESTIGATOR_053], an NK -[ADDRESS_1276621] was observed at a dosing regimen 
which reached 90% receptor occupancy than a dosing regimen reaching 80% receptor 
occupancy [12].   
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276622] a periphe rally-mediated 
component involving modulation of abdominal vagal afferent activity [15].   Additionally, the 
pharmacokinetic profile of tradipi[INVESTIGATOR_909301] -exposure re lationship seen in healthy volunteers.  These two 
factors lead to the possibility that a higher daily dose of tradipi[INVESTIGATOR_909335], a more frequent dosing regimen may be warranted.  
As [ADDRESS_1276623] 85 mg 
BID.  Because gastroparesis requires long term chronic treatment, a long term dosing up to 12 
months is being assessed.  
 
The completed nonclinical and clinical safety studies with tradipi[INVESTIGATOR_909303] a favorable safety 
profile. Clinical laboratory tests, vital signs, 12 -lead ECG, and physical examination (PE) data 
showed no clinically significant alterations due to administra tion of tradipi[INVESTIGATOR_053].  Additionally, 
preclinical studies showed no evidence of a drug -related QT prolongation.  
 
[IP_ADDRESS].  Risk Benefit  
The potential benefit for subjects on continued open label tradipit ant is the possibility of 
experiencing decreased symptoms of gastroparesis while participating in this study. Nonclinical 
and clinical data to date have not indicated any likely toxicity at doses to be used in this study, 
and the drug has been well -tolerat ed in previous clinical studies.  The most commonly reported 
adverse events (≥ 2% and 1.25x placebo) in previous clinical studies were somnolence, 
dizziness, fatigue, and dry mouth.  Noneth eless, as tradipi[INVESTIGATOR_909304], 
there may be unforeseen risks associated with its use.  
 
20.2.3.  Investigational Plan  
 
[IP_ADDRESS].  Overall Phase Design and Plan: Description  
This is a continued open label extension phase. Approximately one hundred fifty (150) patients 
diagnosed with gastroparesis of either diabetic or idiopathic origin that have previously enrolled 
in VLY -VP-686-2301 randomized and open label phases will be as ked to take 85mg tradipi[INVESTIGATOR_909336] 12 hour intervals for 12 months in an open -label fashion. Patient participation will 
include:  
• Day 0, COLE Screening Visit 1 (A/B)  
• Week 4, COLE Visit 2  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
84 • Week 8, Health Assessment Call 1  
• Week 12, COLE Visit 3  
• Week 16, Health Assessment Call 2  
• Week 20, COLE Visit 4  
• Week 24, Health Assessment Call 3  
• Week 28, COLE Visit 5  
• Week 32, Health Assessment Call 4  
• Week 36, Health Assessment Call 5  
• Week 40, COLE Visit 6  
• Week 44, Health Assessment Call 6  
• Week 48, Health Assessment Call 7  
• Week 52, COLE Visit 7  
 
[IP_ADDRESS].  Screening Visit COLE -Visit 1 -A (Day 0)  
 For patients currently enrolled in  VP-VLY -686-2301, this visit should correspond to the Visit 6  
visit such that there is no interruption of participation between phases  if possible.   
During this visit, patients will sign the informed consent. El igibility will be assessed based on 
their current medication use, physical examination (PE), vital signs, ECG, C -SSRS result, urine 
drug screen, urine and serum pregnancy test, if applicable,  and clinical laboratory results  from 
VP-VLY -686-2301 Visit 6 .   
Patients that meet all of the study requirements will be enrolled into the phase . The study staff 
will provide instructions to patients detailing the instructions on how to take tradipi[INVESTIGATOR_053] . Study 
drug w ill be dispensed to the patient.  
 
[IP_ADDRESS].  Screening Visit COLE -Visit 1 -B (Day 0)  
For patients who completed VP-VLY -686-2301 through V isit 6 and would like to enroll in the 
continued open label phase (COLE) after being off study drug for a period of time .   
During this visit, patients will sign the informed consent. El igibility will be assessed based on 
their gastroparesis  diagnosis, their current medication use, medical history, a physical 
examination (PE), vital signs, ECG, C -SSRS, urine drug screen, urine and serum pregnancy test, 
if applicable, and clinical laboratory results.  Patients will complete the since last visit C -SSRS, 
Modified Gastroparesis Cardinal Symptom Index (mGCSI), Modified PAGI -SYM (mPAGI -
SYM), Clinical Global Impression of Severity (CGI -S), Patient Assessment of Upper 
Gastrointestinal Disorder Quality of Life (PAGI -QOL).  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
85 Patients that meet all of the study requirements will be enrolled into the COLE . The study staff 
will confirm the patient’s demographic information and provide instructions to patients detailing 
the instructions on how to take tradipi[INVESTIGATOR_053] .  Study drug w ill be dispensed to the patient.  
 
[IP_ADDRESS].  COLE Visit 2 -Visit 6 (Day 28, Day 84, Day 140, Day 196, Day 280  ± 5 days)  
On COLE Visit 2, COLE Visit 3, COLE Visit 4, COLE Visit 5 and COLE Visit 6, patients will 
return to the site to be queried for any adverse events and updates to t heir current medication 
use. Patients will undergo a physical examination (PE), vital signs, ECG, C -SSRS, urine drug 
screen, urine and serum pregnancy test, if applicable, and clinical laboratory results.  Patients 
will complete the since last visit C -SSRS, Modified Gastroparesis Cardinal Symptom Index 
(mGCSI), Modified PAGI -SYM (mPAGI -SYM), Clinical Global Impression of Severity (CGI -
S), Patient Assessment of  Upper Gastrointestinal Disorder Quality of Life (PAGI -QOL). Daily 
diary compliance will be reviewed, study medication will be collected and reviewed, and new 
study drug w ill be dispensed . 
 
[IP_ADDRESS].  Monthly Call to Subjects to Assess Health (Day 56, Day 112, Day 224, Day 252, 
Day 308, Day 336,  ± 3 days)  
A member of the study team will call patients to assess overall health and query for any adverse 
events or updates to their current medication. Note: An unschedu led visit will be performed if 
medically warranted  in the opi[INVESTIGATOR_689] . 
 
[IP_ADDRESS].  End of Study or Early Termination COLE Visit 7 (Day 364 ± 7 days)  
At the End of Study  COLE  Visit 7 Day 364 ± 7 days or at the time of early termination, s ubjects 
will return to the clinic for safety and efficacy assessments.  Diary and medication compliance 
will be reviewed. Patients will undergo a physical examination (PE), vital signs, ECG, urine 
drug screen, urine and serum pregnancy test, if applicable, and clinical laboratory results.  
Patients will complete the since last visit C -SSRS, Modified Gastroparesis Cardinal Symptom 
Index (mGCSI), Modified PAGI -SYM (mPAGI -SYM), Clinical Global Impression of Severity 
(CGI -S), Patient Assessment of Upper Gastrointestinal Disorder Quality of Life (PAGI -QOL). 
Daily diary compliance will be reviewed, study medication will be collected and reviewed.  
 
Table  9: Schedule of Evaluations  for COLE  
COLE Visit s V1-A 
Screening  V1-B 
Screening  V2 
 V3-V6 
 V7 
EOS/ET  
COLE Study Day  Day 0  Day 0  Day 281 Day 84, 140, 
196, 2801  Day 3652 
VP-VLY -686-2301 EOS Procedures  X     
Informed Consent Form (ICF)3 X X    
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
86 COLE Visit s V1-A 
Screening  V1-B 
Screening  V2 
 V3-V6 
 V7 
EOS/ET  
COLE Study Day  Day [ADDRESS_1276624] demography and medical 
history  X X    
Prior/concomitant medications  X X X X X 
Adverse Event (AE) Query4 X X X X X 
Serum β -HCG (for WOCBP)   X   X 
Urine pregnancy test (for WOCBP)    X X  
TSH, T4   X X X X 
Urine D rug Screen   X X X X 
HbA1c, h ematology, chemistry, and 
urinalysis   X X X X 
12-lead resting ECG   X X X X 
Vital Signs and Body Measurements5  X X X X 
Physical Examination (PE)   X X X X 
C-SSRS6  X X X X 
mGCSI 7  X X X X 
mPAGI -SYM   X X X X 
PAGI -QOL    X X X X 
Patient Global Impression of Change 
(PGI -C)    X X X 
Clinical Global Impression of 
Severity (CGI -S)   X X X X 
Study medication dispensation   X X X X  
Study medication collection & 
compliance    X X X 
Subject diary instruction   X X    
Subject diary review    X X X 
Schedule Monthly Call    X X  
EOS      X 
Gastroparesis Core Symptom Daily 
Diary  (GCSDD)                                                                       
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
87 COLE Visit s V1-A 
Screening  V1-B 
Screening  V2 
 V3-V6 
 V7 
EOS/ET  
COLE Study Day  Day 0  Day 0  Day 281 Day 84, 140, 
196, 2801  Day 3652 
VP-VLY -686-2301 EOS Procedures  X     
Health Asse ssment Call between 
Visits (every 4 weeks)    X X  
EOS= End of Study ; WOCBP = Women of Child -bearing Potential; ECG = electrocardiogram; C -SSRS = 
Columbia Suicide Severity Rating Scale; mGCSI = modified Gastroparesis Cardinal Symptom Index; PAGI -QOL = 
Patient Assessment of Upper Gastrointestinal Symptoms – Quality of Life  
1 within ± 5 days  
2 within ± 7 days  
3 Informed consent will be obtained prior to the performance of any study procedure(s)  
4 Adverse event collection will begin at the time the ICF is signed.  
5 Vital sign collection at all visits. Height collection at V1. Body weight collection at V1 -V7. 
6 The Screening/Baseline C -SSRS will occur at V1 -B.  The Since Last Visit C -SSRS will occur at all other visits.  
7mGCSI questions on symptom changes  (Part II) will only be administered at V 2- V7.  
 
20.2.4.  Selection and Withdrawal Criteria of Subjects for the OLE Phase  
 
[IP_ADDRESS].  Inclusion Criteria  
A subject is eligible for enrollment into the COLE phase of this study if he/she meets the following 
criteria:  
• Has completed  the randomization phase and open label phase through Visit 6 (Study 
Day 84);  
• Is willing to provide an additional written informed consent for the COLE phase  if 
enrolled in study prior to COLE becoming available . 
 
See Section  6.1 for complete study Inclusion Criteria and Section  6.2 for complete study 
Exclusion Criteria.  
 
[IP_ADDRESS].  Early Withdrawal of Subjects  
The term “discontinuation” refers to the subject’s premature withdrawal from the study before 
completing all scheduled evaluations.  
 
Subjects may voluntarily withdraw from the COLE at any time for any reason. Subjects may 
also be discontinued from the study for any of the following reasons:  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
88 • If in the Investigator’s judgment, continuation in the study may prove harmful to the 
subject.  Such a decision may be precipi[INVESTIGATOR_152208], including changes in 
vital signs, physical examination, ECG, or laboratory tests.  The Investigator will 
maintain autonomy in making medical/safety decisions regarding the subject’s 
continued participation in the trial.  Clinically notable abnormalities in vital signs or 
laboratory tests are provided in Appendices  20.[ADDRESS_1276625]’s continued participation;  
• Noncompliance;  
 
For subjects withdrawing from the study prematurely, all efforts wil l be made to perform the  
COLE Visit 7  Early Termination procedures.  
 
Documented reason:    
It will be documented whether or not  each subject completed the clinical study.  If, for any subject, 
study treatment or observations were discontinued, the reason will be recorded (only 1 choice is 
acceptable) on the electronic case report form (electronic CRF).  Acceptable reasons for a su bject 
discontinuing participation in this clinical study are as follows:  
9. Protocol deviation (including noncompliance to study requirements)  
10. Adverse event(s) (including abnormal laboratory values, and abnormal test procedures)  
11. Pregnancy  
12. Lost to follow -up 
13. Death  
14. Subject withdrew consent  
15. Unsatisfactory therapeutic effect  
16. Other (specify).  
20.2.5.  Treatment of Subjects  
[IP_ADDRESS].  Dosing  
Subjects will be dispensed study medication under open -label  conditions at the study visits 
indicated in the Schedule of Evaluations  for COLE (Table  9).  Subjects will be instructed to take 
one capsule of study medication every day in the morning, and one capsule of study medication 
every day in the evening approximately 12 hours later. Each capsule will contain either 85 mg of 
tradipi[INVESTIGATOR_053] . 
 
[IP_ADDRESS].  Guidance for Taking Study Medication  
Subjects should be instructed to take study medication approximately every [ADDRESS_1276626] 30 minutes 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276627] 
capsule can be identified in the emesis, a second capsule should be administered.  
 
20.2.6.   Concomitant Medication During the COLE Phase  
The administration of concomitant medication (including OTC medication) will be clearly 
documented on the concomitant medication CRF page.  
In general, concomitant medications that may interfere with the assessment of the efficacy and 
safety of tradipi[INVESTIGATOR_909328].  
 
[IP_ADDRESS].  Prohibited Medication  
Prohibited medications and treatments are prohibited from the screening visit (or 4 weeks prior to 
the Randomization Visit when a washout is required) through the end of study participation. 
Questions regarding the use of concomitant medications not listed  should be directed to the 
Medical Monitor.  
All medications prohibited during the randomization phases ( Section  7.2.1 ) will also be prohibited 
during this phase.  
 
[IP_ADDRESS].  Rescue Medication  
Anti-nausea or antiemetic medication that is not administered on a stable daily dosing regimen 
is considered rescue medication. Patients may use rescue medication per the Rescue Medication 
Guidelines ( Section  [IP_ADDRESS] ). 
 
20.2.7.  Treatment Compliance  
Compliance in this study will be assessed by [CONTACT_737]. The Investigator will consider 
patient interviews as well as returned capsules when assessing compliance. Subjects who were 
not fully compliant will be re -educated by [CONTACT_909371].  
Any overdose that occurs during study participation must be recorded on the overdose CRF. An 
overdose (intentional or accidental) is defined as the following: >3 capsules of open label study 
medication taken within a 24 -hour period (except when re -administ ered within the guidance of 
Section  7.1.2 ). 
 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
90 20.2.8.  Treatment Assignment  
At COLE  Visits 1-6, (Table  9), study personnel will dispense enough COLE medication to the 
subject to last until the next scheduled visit.  
 
20.2.9.  Study Drug, Packaging, and Labeling  
Tradipi[INVESTIGATOR_909329], hard gelatin capsules provided as a strength of 85 mg. The 
85 mg capsule formulation also contains spray -dried lactose monohydrate, microcrystalline 
cellulose (Avicel PH102 and PH200), povidone, croscarmellose sodium,  sodium lauryl sulfate, 
and magnesium stearate as excipi[INVESTIGATOR_840].  
 
Study medication capsules will be provided in high -density polyethylene (HDPE) bottles with a 
child -resistant cap containing desiccant. Each bottle will contain [ADDRESS_1276628]’s source 
documents before the bottle is dispensed to the subject.  
 
Study medication should be stored at 20 -25 °C with excursions permitted to 15 -30 °C. Capsules 
should not be crushed or broken, but should be swallowed whole. Study medication will be 
dispensed to only randomized subjects at the study site.  
 
20.2.10.  Study Medication Materials and Management  
See Section  8 for information on study medication packaging, storage and accountability.  
 
20.2.11.  Study Assessments per Visit  
[IP_ADDRESS].  COLE Screening Visit  A or B  (Visit 1, COLE Day 0)  
The following will be performed after the subject signs the informed consent form:  
• Review of inclusion/exclusion criteria  
• Collection of demographic information, medical history, and prior and concurrent 
medications;   
• Vital sign and body measurements  
• Patients who are coming directly from VP -VLY -686-2301 Visit 6  can coordinate this 
visit with VP -VLY -686-2301 Visit 6.  
• Patients who are returning after a gap (Vist 1 -B) will  perform the following additional 
procedures:  
− Physical examination (PE) (excluding pelvic, rectal and breast examinations 
unless clinically indicated)  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
91 −  ECG  
− Screening C -SSRS questionnaire  
− Clinical laboratory assessments: hematology, chemistry (including estimated 
creatinine clearance (eCLcr; based on the Cockcroft -Gault equation) , urinalysis, 
HbA1c, thyroid stimulating hormone (TSH), thyroxine (T4), urine drug screen,  
− Serum pregnancy test and collection of menstrual cycle information (for females 
of child -bearing potential)  
− Modified Gastroparesis Cardinal Symptom Index (mGCSI) Part I  
− Modified PAGI -SYM (mPAGI -SYM)  
− Gastroparesis Treatment Benefit Survey (GTBS)  
• Study medication instruction and dispensation  
Collection of adverse event information will begin at the time the ICF is signed.  Subjects will 
be set up on phone diary and instructed to begin completing their diary daily  (Section  10.1.1 ). 
 
[IP_ADDRESS].  COLE Visit 2 -Visit 6 (COLE Day 28, Day 84, Day 140, Day 196, Day 280, ± 5 
days)  
On COLE Visit [ADDRESS_1276629]’s continued eligibility:  
• Adverse Event query  
• Concomitant medication review  
• Urine pregnancy test (for females of child -bearing potential)  
• Semi -supi[INVESTIGATOR_050] r outine vital signs (body temperature, respi[INVESTIGATOR_697], blood pressure, 
and pulse)   
• ECG  
• Physical examination (PE) (excluding pelvic, rectal and breast examinations unless 
clinically indicated)  
• Clinical laboratory assessments (HbA1C, hematology, chemistry  (including e CLcr; 
based on the Cockcroft -Gault equation ), urinalysis , thyroid stimulating hormone 
(TSH), thyroxine (T4), and urine drug screen ) 
• Since last visit C -SSRS  
• Diary review  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Global Impression of Change (PGI -C) 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
92 • Clinical Global Impression of Severity (CGI -S) 
• Study medication collection and review  
• Study medication dispensation  
• Schedule Monthly Calls  
 
[IP_ADDRESS].  COLE Visit 7/End of Study/Early Termination (COLE Day 365, ± 7 days)  
• Adverse Event query  
• Concomitant medication review  
• Full PE (excluding pelvic, rectal and breast examinations unless clinically indicated)  
• Laboratory evaluations ( HbA1C, hematology, chemistry  (including e CLcr; based on 
the Cockcroft -Gault equation ), urinalysis , thyroid stimulating hormone (TSH), 
thyroxine (T4), and urine drug screen ) 
• Serum pregnancy test and collection of menstrual cycle information (for females of 
child -bearing potential)  
• ECG  
• Semi -supi[INVESTIGATOR_050] r outine vital signs (body temperature, respi[INVESTIGATOR_697], blood pressure, 
and pulse)  and weight  
• Since last visit C -SSRS  
• Diary review  
• Modified Gastroparesis Cardinal Symptom Index (mGCSI)  
• Modified PAGI -SYM (mPAGI -SYM)  
• Patient Global Impression of Change (PGI -C) 
• Patient Assessment of Upper Gastrointestinal Disorder  Quality of Life (PAGI -QOL)  
• Clinical Global Impression of Severity (CGI -S) 
• Study medication collection and review  
• Record EOS  
 
[IP_ADDRESS].  Unscheduled Visits 
Unscheduled visits may be performed at any time at the discretion of the Investigator.  
 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
93 [IP_ADDRESS].  Monthly Calls to Patients ( COLE Day 56, Day 112, Day 224, Day 252, Day 308, 
Day 336, ± 3 days)  
Members of the study team will call patients between visits to assess overall health and query 
for any adverse events or updates to their current medication.  An unschedu led visit will be 
performed if medically warranted  in the opi[INVESTIGATOR_689] . 
 
20.2.12.  Efficacy Assessments  
The efficacy  assessments should be conducted as specified in the Schedule of Evaluation s for 
COLE (Table  9).  These assessments include:  the Gastroparesis Core Symptom Daily Diary 
(GCSDD) , Modified Gastroparesis Cardinal Symptom Index (mGCSI), Modified PAGI -SYM 
(mPAGI -SYM), Patient Global Impression of Change (PGI -C), and the Patient Assessment of 
Upper Gastrointestinal Disorders -QOL (PAGI -QOL) (see Section  10.1.1  for a description of the 
patient reported outcomes) and the Clinician Global Impression – Severity (CGI -S) (see 
Section  10  for complete description s of the assessment s). 
20.2.13.  Safety Assessments  
The safety assessments should be conducted as specified in the Schedule of  Evaluation s for COLE 
(Table  9).  These assessments include: the regular monitoring and recording of all adverse events 
and serious adverse events (SAEs); the regular monitoring of hematology, blood biochemistry and 
urinalysis values; the regular monitoring of vital signs; the regular monitoring of suicidal ideation 
and behavior , and the performance of physical examinations, and electrocardiograms.   
 
Refer to  Section  11 for additional details relating to the collection of safety assessments  and 
adverse event reporting . 
 
20.2.14.  Statistical Methods  
Statistical analysis for the COLE phase will be based on data summaries, using similar layouts as 
for the randomization phase, an d will be exploratory in nature (See Section  13 for further details).  
 
 
20.3. Labo ratory Ranges Used to Identify  Clinically Notable Abnormal 
Laboratory Values  
Criteria for identifying laboratory values as Potentially Clinically Notable Abnormalities are 
based on the Guidelines for the Division of Neuropharmacological Drug Products, US Food and 
Drug Administration (revised on April 2, 1987).  
 
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment [ADDRESS_1276630] Units  SI Units  
Chemistry    
SGOT   3 x Upper Limit Normal   
SGPT   3 x Upper Limit Normal   
Alkaline Phosphatase   3 x Upper Limit Normal    
LDH   3 x Upper Limit Normal   
BUN   30 mg/dL   10.7 M 
Creatinine   2.0 mg/dL   176.8 M 
Uric Acid                         Male   10.5 mg/dL   624.6 M 
                                       Female   8.5 mg/dL   505.6 M 
Bilirubin (Total)   2.0 mg/dL   34.2 M 
Hematology    
Hematocrit                      Male   37%  
                                       Female   32%  
Hemoglobin                    Male   11.5 g/dL   
                                       Female   9.5 g/dL   
Platelets   75,000/mm3 or  700,000/mm3  75 x 109/L or  700 x 109/L 
Leukocytes   2,800/mm3 or  16,000/mm3  2.8 x 109/L or  16 x 109/L 
Eosinophils   10%  
Neutrophils   15%  
Urinalysis    
Protein  Increase of  2 units   
Glucose  Increase of  2 units   
Casts  Increase of  2 units   
 
20.4. Vital Signs Values  
Criteria for identifying vital signs values as Potentially Clinically Notable Abnormalities are based 
on the Guidelines for the Division of Neuropharmacological Drug Products, US Food and Drug 
Administration (revised on April 2, 1987).  
 
Variable     Criteria        Change Relative to Baseline  
Heart Rate     ≥ 120 bpm       and an    increased of ≥ 15 bpm  
      ≤ 50 bpm    and a    decrease of ≥ 15 bpm  
VP-VLY-686-2301                                                                              Vanda Pharmaceuticals  Inc. 
Clinical Study Protocol – Amendment 9                                          26 November  2018        
Confidential  
95  
Systolic  
Blood Pressure   ≥ 180 mmHg       and an    increase of ≥ 20 mmHg  
      ≤ 90 mmHg       and a    decrease of ≥ 20 mmHg  
 
Diastolic  
Blood Pressure   ≥ 105 mmHg       and an    increase of ≥ 15 mmHg  
      ≤ 50 mmHg       and a    decrease of ≥ 15 mmHg  
 
Temperature    ≥ 38.3  oC        and a    change of ≥ 1.1  oC 
      ≥ 101  oF           and a    change of ≥ 2  oF         
         
Weight     --         change of ≥ 7% body weight  
 